Polypeptide containing modified IL-2 polypeptide and uses thereof
Modified IL-2 polypeptides with reduced CD25 and CD122 affinity address the toxicity and efficacy limitations of existing IL-2 therapies, enhancing T-cell proliferation and cancer treatment efficacy.
Patent Information
- Application Number
- KR1020217024431
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-01-07
- Filing Date
- 2020-01-06
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2040-01-06
AI Technical Summary
Current IL-2 therapies for cancer treatment, such as recombinant human IL-2 (rhIL-2), suffer from severe toxicity due to rapid receptor-mediated internalization and degradation, leading to short half-lives and vascular leakage syndrome, while existing checkpoint inhibitor therapies have limited response rates.
Development of modified IL-2 polypeptides with reduced affinity for CD25 and CD122, combined with targeting moieties, to enhance T-cell modulation and cancer treatment efficacy.
The modified IL-2 polypeptides demonstrate enhanced T-cell proliferation and reduced toxicity, offering improved therapeutic outcomes for various cancers with potential synergistic effects when combined with other therapeutic agents.
Smart Images

Figure 112021088896332-PCT00014_ABST
Abstract
Description
Technology Field
[0001] Cross-reference regarding related applications
[0002] This application claims the benefit of priority of U.S. Provisional Application No. 62 / 789,075 filed January 7, 2019, the entirety of which is incorporated herein by reference for any purpose.
[0003] Technology field
[0004] The present invention relates to a modified IL-2 having reduced affinity for CD25 and CD122 and to such modified IL-2 fused to a targeting moiety. The present invention relates to a method of using a modified IL-2 and a polypeptide comprising the modified IL-2, including a method for treating cancer, without limitation. Background Technology
[0005] IL-2 is a potent cytokine that stimulates T and NK cell proliferation through the heterotrimeric IL-2 receptor (IL-2R), composed of CD25, CD122, and CD132, or the heterotrimeric IL-2 receptor, composed solely of CD122 and CD132. Both forms of IL-2R are potent mediators of T cell survival, proliferation, and overall activation. IL-2 is generally produced by T cells and NK cells upon activation and mediates cis and trans signaling in the local microenvironment. IL-2R signaling can induce the differentiation of naive T cells into effector and memory T cells, and can also stimulate suppressor regulatory T cells. Although the trimeric form of IL-2R has a higher affinity for IL-2 than the dimeric form, both possess significantly high affinity and undergo rapid receptor-mediated internalization and degradation, resulting in extremely short half-lives. Recombinant human IL-2 (rhIL-2, proleukin) is clinically used to treat renal cell carcinoma and malignant melanoma, but it is associated with severe toxicity. Vascular leakage syndrome is a major toxicity issue in cancer patients treated with proleukin due to the impact of IL-2 signaling on endothelial cells expressing high affinity IL-2R.
[0006] T cells are activated through the ligation of TCRs with neighboring cells presenting MHCs containing bound complementary peptides, leading to the clustering of TCR complexes and signal transduction via NFATs. Co-stimulation of T cells via CD28 is induced by CD80 and CD86, which enhance T cell activation. After initial activation, T cells upregulate various proteins, including cytokine receptors as well as many co-stimulatory and checkpoint receptors that play a role in regulating T cell responses.
[0007] Sustained antitumor clinical responses of antagonist antibodies against checkpoint receptors such as CTLA-4, PD-1, and PD-L1 have recently been reported. However, even in the most responsive indications, the response rate is limited to approximately 30% of patients. Therefore, improved T-cell modulatory therapies are needed.
[0008] Polypeptides comprising a modified IL-2 comprising at least one substitution at at least one amino acid position are provided herein. In some embodiments, the modified IL-2 has reduced binding affinity for CD25, CD122, and / or IL-2R compared to wild-type IL-2. In some embodiments, the modified IL-2 has reduced activity on resting or activated T cells compared to wild-type IL-2.
[0009] Embodiment 1. A polypeptide comprising a modified IL-2, wherein the modified IL-2 comprises at least one substitution at at least one amino acid position selected from P65, D84, E95, M23, and H16.
[0010] Embodiment 2. The polypeptide in Embodiment 1, wherein the modified IL-2 is modified human IL-2.
[0011] Embodiment 3. A polypeptide in which the amino acid position in Embodiment 1 or Embodiment 2 corresponds to the amino acid position in Sequence No. 1.
[0012] Embodiment 4. A polypeptide in any one of Embodiments 1 to 3, wherein the modified IL-2 comprises a substitution at amino acid position P65.
[0013] Embodiment 5. Polypeptide in Embodiment 4, wherein the substitution is selected from P65R, P65E, P65K, P65H, P65Y, P65Q, P65D, and P65N.
[0014] Example 6. A polypeptide in any one of Examples 1 to 5, wherein the modified IL-2 comprises a substitution at amino acid position H16.
[0015] Embodiment 7. Polypeptide in Embodiment 6, wherein the substitution is selected from H16A, H16G, H16S, H16T, H16V, and H16P.
[0016] Embodiment 8. A polypeptide in any one of Embodiments 1 to 7, wherein the modified IL-2 comprises a substitution at amino acid position D84.
[0017] Embodiment 9. Polypeptide in Embodiment 8, wherein the substitution is selected from D84S, D84G, D84A, D84T, D84V, and D84P.
[0018] Embodiment 10. A polypeptide in any one of Embodiments 1 to 9, wherein the modified IL-2 comprises substitutions at amino acid positions P65, H16, and D84.
[0019] Embodiment 11. The polypeptide of Embodiment 10, wherein the modified IL-2 comprises the substitutions P65R, H16A, and D84S.
[0020] Embodiment 12. A polypeptide in any one of Embodiments 1 to 11, wherein the modified IL-2 comprises a substitution at amino acid position M23.
[0021] Embodiment 13. Polypeptide in Embodiment 12, wherein the substitution is selected from M23A, M23G, M23S, M23T, M23V, and M23P.
[0022] Embodiment 14. The polypeptide of Embodiment 13, wherein the modified IL-2 comprises the substitutions P65R, H16A, D84S, and M23A.
[0023] Embodiment 15. A polypeptide in any one of Embodiments 1 to 14, wherein the modified IL-2 comprises a substitution at amino acid position E95.
[0024] Embodiment 16. Polypeptide in Embodiment 15, wherein the substitution is selected from E95Q, E95G, E95S, E95T, E95V, E95P, E95H, and E95N.
[0025] Embodiment 17. The polypeptide of Embodiment 16, wherein the modified IL-2 comprises the substitutions P65R, H16A, D84S, and E95Q.
[0026] Embodiment 18. The polypeptide of claim 17, wherein the modified IL-2 comprises the substitutions P65R, H16A, D84S, M23A, and E95Q.
[0027] Embodiment 19. A polypeptide in which, in any one of Embodiments 1 to 18, the modified IL-2 comprises a substitution at amino acid position F42.
[0028] Embodiment 20. A polypeptide in which the substitution in F42 of Embodiment 19 is selected from F42K, F42A, F42R, F42A, F42G, F42S, and F42T.
[0029] Embodiment 21. A polypeptide in any one of Embodiments 1 to 20, wherein the modified IL-2 comprises at least one substitution at at least one amino acid position selected from Y45 and L72.
[0030] Embodiment 22. The polypeptide of Embodiment 21, wherein the modified IL-2 comprises at least one substitution selected from Y45A and L72G.
[0031] Embodiment 23. A polypeptide in any one of Embodiments 1 to 22, wherein the modified IL-2 comprises at least one substitution at at least one amino acid position selected from T3 and C125.
[0032] Embodiment 24. The polypeptide of Embodiment 23, wherein the modified IL-2 comprises at least one substitution selected from T3A and C125A.
[0033] Embodiment 25. In any one of Embodiments 1 to 24, the modified IL-2 is H16A-F42K; D84S-F42K; E15S-F42K; M23A-F42K; E95Q-F42K; P65R-H16A; P65R-D84S; P65R-E15S; P65R-M23A; P65R-E95Q; T3A-C125S; T3A-P65R-C125S; T3A-H16A-C125S; T3A-D84S-C125S; T3A-H16A-P65R-C125S; T3A-P65R-D84S-C125S; A polypeptide comprising a set of substitutions selected from T3A-H16A-P65R-D84S-C125S; T3A-H16A-M23A-P65R-D84S-C125S; T3A-H16A-P65R-D84S-E95Q-C125S, and T3A-H16A-M23A-P65R-D84S-E95Q-C125S.
[0034] Embodiment 26. A polypeptide in which the modified IL-2 of Embodiment 25 comprises a set of substitutions and does not include any additional substitutions.
[0035] Embodiment 27. In any one of Embodiments 1 to 26, the modified IL-2 is a polypeptide comprising an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 84.
[0036] Embodiment 28. A polypeptide in which, in any one of Embodiments 1 to 27, the modified IL-2 comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 3-9, 11-21, and 23-31.
[0037] Embodiment 29. A polypeptide in which, in any one of Embodiments 1 to 28, the modified IL-2 comprises an amino acid sequence selected from SEQ ID NOs: 3-9, 11-21, and 23-31.
[0038] Example 30. A polypeptide comprising an Fc region in any one of Examples 1 to 29.
[0039] Embodiment 31. A polypeptide in which the modified IL-2 of Embodiment 30 is fused to the N-terminus or C-terminus of the Fc region.
[0040] Embodiment 32. A polypeptide according to Embodiment 30 or Embodiment 31, wherein the Fc region comprises a substitution at the Kabat amino acid position T366.
[0041] Embodiment 33. A polypeptide according to Embodiment 32, wherein the Fc region comprises a T366W substitution.
[0042] Embodiment 34. A polypeptide according to Embodiment 31, wherein the Fc region comprises at least one substitution at at least one kavat amino acid position selected from T366, L368, and Y407.
[0043] Embodiment 35. Polypeptide in which the Fc region of Embodiment 34 comprises T366S, L368A, and Y407V mutations.
[0044] Embodiment 36. A polypeptide in which, in any one of Embodiments 30 to 35, the Fc region comprises a substitution at a kavat position selected from S354 and Y349.
[0045] Embodiment 37. Polypeptide according to Embodiment 36, wherein the Fc region comprises an S354C or Y349C substitution.
[0046] Embodiment 38. A polypeptide in which, in any one of Embodiments 30 to 37, the Fc region comprises a substitution at the kavat amino acid position H435.
[0047] Embodiment 39. A polypeptide according to Embodiment 38, wherein the Fc region comprises a substitution selected from H435R and H435K.
[0048] Embodiment 40. A polypeptide in which, in any one of Embodiments 30 to 39, the Fc region comprises at least one substitution at at least one kavat amino acid position selected from M252 and M428.
[0049] Embodiment 41. A polypeptide in which the Fc region of Embodiment 40 comprises M252Y and M428V substitutions.
[0050] Embodiment 42. A polypeptide in which, in any one of Embodiments 30 to 41, the Fc region comprises deletions of carbat amino acids E233, L234, and L235.
[0051] Embodiment 43. A polypeptide in which, in any one of Embodiments 30 to 41, the Fc region comprises at least one substitution at at least one amino acid position selected from L234, L235, and P329.
[0052] Embodiment 44. Polypeptide according to Embodiment 43, wherein the Fc region comprises L234A, L235A, and P329G substitutions.
[0053] Embodiment 45. A polypeptide in which, in any one of Embodiments 30 to 44, the Fc region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected from SEQ ID NO: 47-83.
[0054] Embodiment 46. A polypeptide in which, in any one of Embodiments 30 to 44, the Fc region is part of a heavy chain invariant region.
[0055] Embodiment 47. A polypeptide according to Embodiment 46, wherein the heavy chain constant region is an IgG constant region.
[0056] Embodiment 48. Polypeptide according to Embodiment 47, wherein the heavy chain constant region is an IgG1, IgG2, IgG3, or IgG4 constant region.
[0057] Embodiment 49. A polypeptide in which, in any one of Embodiments 30 to 48, the modified IL-2 is fused to the C-terminus of the Fc region or the heavy chain constant region.
[0058] Embodiment 50. A polypeptide in which the modified IL-2 of Embodiment 49 is fused to the C-terminus of the Fc region or the heavy chain constant region through a linker comprising 1 to 20 amino acids.
[0059] Embodiment 51. In Embodiment 50, the linker is a polypeptide comprising a glycine amino acid.
[0060] Embodiment 52. The polypeptide of Embodiment 51, wherein the linker comprises glycine and serine amino acids.
[0061] Example 53. A polypeptide in which, in any one of Examples 50 to 52, most or all of the amino acids in the linker are glycine and serine.
[0062] Embodiment 54. In any one embodiment of Embodiments 30 to 33, Embodiment 42, and Embodiments 49 to 53, the polypeptide comprises the amino acid sequence of SEQ ID NO: 86, 87, 102, 103, or 104.
[0063] Example 55. A polypeptide comprising at least one antigen-binding domain in any one of Examples 1 to 54.
[0064] Embodiment 56. The polypeptide of Embodiment 55, wherein the polypeptide comprises 2, 3, or 4 antigen-binding domains.
[0065] Embodiment 57. A polypeptide according to Embodiment 55 or Embodiment 56, wherein at least one antigen-binding domain specifically binds to a T-cell antigen or a natural killer cell antigen.
[0066] Embodiment 58. In any one of Embodiments 55 to 57, at least one antigen-binding domain is CD4 + T-cell antigen or CD8 + A polypeptide that specifically binds to T-cell antigens.
[0067] Embodiment 59. In Embodiment 58, at least one antigen binding domain is an activated CD4 + T-cells or activated CD8 + A polypeptide that specifically binds to antigens on T-cells.
[0068] Embodiment 60. A polypeptide in which, in any one of Embodiments 55 to 59, at least one antigen-binding domain is an agent.
[0069] Embodiment 61. A polypeptide in which the antigen-binding domain is an antagonist in any one of Embodiments 55 to 59.
[0070] Embodiment 62. A polypeptide in any one of Embodiments 55 to 61, wherein at least one antigen-binding domain specifically binds to PD-1, CTLA-4, LAG3, TIM3, 4-1BB, OX40, GITR, CD8a, CD8b, CD4, NKp30, NKG2A, TIGIT, TGFβR1, TGFβR2, Fas, NKG2D, NKp46, PD-L1, CD107a, ICOS, TNFR2, or CD16a.
[0071] Embodiment 63. A polypeptide in which, in any one of Embodiments 55 to 62, at least one antigen-binding domain specifically binds to PD-1.
[0072] Embodiment 64. A polypeptide in which, in any one of Embodiments 55 to 63, at least one antigen-binding domain is a human or humanized antigen-binding domain.
[0073] Embodiment 65. A polypeptide in which, in Embodiment 64, each antigen-binding domain is independently a human or humanized antigen-binding domain.
[0074] Embodiment 66. A polypeptide in which, in any one of Embodiments 55 to 65, at least one antigen-binding domain comprises a VHH domain.
[0075] Embodiment 67. Polypeptide according to Embodiment 66, wherein each antigen-binding domain comprises a VHH domain.
[0076] Embodiment 68. A polypeptide in which, in any one of Embodiments 55 to 65, at least one antigen-binding domain comprises a VH domain and a VL domain.
[0077] Embodiment 69. The polypeptide of Embodiment 68, wherein at least one antigen-binding domain comprises the VH domain and VL domain of an antibody selected from pembrolizumab, nivolumab, AMP-514, TSR-042, STI-A1110, ipilimumab, tremelimumab, urelumab, utomilumab, atezolizumab, and durvalumab.
[0078] Embodiment 70. A polypeptide according to Embodiment 68 or Embodiment 69, wherein at least one antigen-binding domain comprises a short-chain Fv (scFv).
[0079] Embodiment 71. The polypeptide of Embodiment 68 or Embodiment 69, wherein the polypeptide comprises a heavy chain constant region, the VH domain is fused to the heavy chain constant region, and the VL domain is associated with the VH domain.
[0080] Embodiment 72. A polypeptide in which the VL domain of Embodiment 71 is fused to a light chain constant region.
[0081] Embodiment 73. A polypeptide in which the light chain invariant region of Embodiment 72 is selected from kappa and lambda.
[0082] Embodiment 74. A polypeptide in which, in any one of Embodiments 55 to 73, each antigen-binding domain is identical.
[0083] Embodiment 75. A polypeptide in which, in any one of Embodiments 55 to 74, each antigen-binding domain specifically binds to the same antigen polypeptide.
[0084] Embodiment 76. A polypeptide in any one of Embodiments 55 to 73, wherein at least one of the antigen-binding domains specifically binds to an antigen different from at least one of the remaining antigen-binding domains.
[0085] Embodiment 77. A polypeptide in any one of Embodiments 55 to 73, wherein at least one antigen-binding domain specifically binds to PD-1, and at least one other antigen-binding domain specifically binds to a T-cell antigen or natural killer cell antigen other than PD-1.
[0086] Embodiment 78. A polypeptide in any one of Embodiments 55 to 77, wherein at least one antigen-binding domain binds to PD-1, CTLA-4, LAG3, TIM3, 4-1BB, OX40, GITR, CD8a, CD8b, CD4, NKp30, NKG2A, TIGIT, TGFβR1, TGFβR2, Fas, NKG2D, NKp46, PD-L1, CD107a, ICOS, TNFR2, or CD16a.
[0087] Example 79. In any one of Examples 31 to 78, the polypeptide is a polypeptide that forms a homodimer under physiological conditions.
[0088] Embodiment 80. A polypeptide in any one of Embodiments 1 to 79, wherein the modified IL-2 binds to human IL-2R with an affinity at least 2, 3, 4, 5, 6, 7, 8, 9, at least 10, at least 20, at least 30, at least 50, or at least 100 times lower than the affinity of human wild-type IL-2 for IL-2R.
[0089] Example 81. A complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is a polypeptide of any one of Examples 1 to 79.
[0090] Embodiment 82. A complex in which, in Embodiment 81, the first polypeptide comprises a first Fc region and the second polypeptide comprises a second Fc region.
[0091] Embodiment 83. A complex in which, in Embodiment 81 or Embodiment 82, each Fc region is an isotype selected from human IgG1, IgG2, IgG3, and IgG4.
[0092] Embodiment 84. A complex in which, in Embodiment 83, each Fc region is human IgG1.
[0093] Embodiment 85. A complex in which, in any one of Embodiments 81 to 84, each Fc region comprises a deletion of amino acids E233, L234, and L235.
[0094] Embodiment 86. A complex in which, in any one of Embodiments 81 to 85, each Fc region comprises an H435R or H435K mutation.
[0095] Embodiment 87. A complex in any one of Embodiments 81 to 86, wherein the Fc region comprises mutants M252Y and M428L or mutants M252Y and M428V.
[0096] Embodiment 88. A complex in any one of Embodiments 81 to 87, wherein the first Fc region or the second Fc region comprises the T366W mutation, and the other Fc region comprises the mutations T366S, L368A, and Y407V.
[0097] Embodiment 89. A complex in which, in Embodiment 88, the first Fc region or the second Fc region comprises an S354C mutation.
[0098] Embodiment 90. A complex in which, in any one of embodiments 81 to 89, each Fc region independently comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected from SEQ ID NO: 47-83.
[0099] Embodiment 91. A complex in any one of Embodiments 81 to 90, wherein the second polypeptide does not contain modified IL2.
[0100] Embodiment 92. A complex in any one of Embodiments 81 to 91, wherein the first polypeptide comprises at least one antigen-binding domain.
[0101] Embodiment 93. A complex in which, in any one of Embodiments 81 to 92, the second polypeptide comprises at least one antigen-binding domain.
[0102] Embodiment 94. A complex in any one of Embodiments 81 to 93, wherein the first polypeptide comprises a first antigen-binding domain, an Fc region, and modified IL-2.
[0103] Embodiment 95. A complex in which, in Embodiment 94, the first antigen-binding domain is fused to the N-terminus of the Fc region and the modified IL-2 is fused to the C-terminus of the Fc region.
[0104] Embodiment 96. A complex in which, in Embodiment 94 or Embodiment 95, the second polypeptide comprises a second antigen-binding domain and an Fc region.
[0105] Embodiment 97. A complex in which, in Embodiment 96, the first antigen-binding domain and the second antigen-binding domain are the same or different.
[0106] Example 98. In Example 97,
[0107] a) Both the first antigen-binding domain and the second antigen-binding domain bind to PD-1;
[0108] b) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to LAG3;
[0109] c) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to CTLA-4;
[0110] d) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to 4-1BB;
[0111] e) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to OX40;
[0112] f) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to GITR;
[0113] g) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to CD8a;
[0114] h) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to CD8b;
[0115] i) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to CD4;
[0116] j) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to NKp30;
[0117] k) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to NKG2A;
[0118] l) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to TIGIT;
[0119] m) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to NKG2D;
[0120] n) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to TGFBR2;
[0121] o) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to Fas;
[0122] p) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to CD107a;
[0123] q) The first antigen-binding domain binds to PD-1, and the second antigen-binding domain binds to NKp46;
[0124] r) The first antigen-binding domain binds to CD8a, and the second antigen-binding domain binds to TGFRβR2;
[0125] s) The first antigen-binding domain binds to CD8a, and the second antigen-binding domain binds to Fas;
[0126] t) The first antigen-binding domain binds to NKG2D, and the second antigen-binding domain binds to TGFRβR2;
[0127] u) The first antigen-binding domain binds to NKG2D, and the second antigen-binding domain binds to Fas;
[0128] v) The first antigen-binding domain binds to NKG2A, and the second antigen-binding domain binds to TGFRβR2;
[0129] w) The first antigen-binding domain binds to NKG2A, and the second antigen-binding domain binds to Fas;
[0130] x) The first antigen-binding domain binds to NKp46, and the second antigen-binding domain binds to TGFRβR2, or;
[0131] y) The first antigen-binding domain binds to NKp46, and the second antigen-binding domain binds to Fas;
[0132] z) The first antigen-binding domain binds to CTLA-4, and the second antigen-binding domain binds to LAG3;
[0133] aa) The first antigen-binding domain binds to CTLA-4, and the second antigen-binding domain binds to Tim3;
[0134] bb) The first antigen-binding domain binds to CTLA-4, and the second antigen-binding domain binds to OX40;
[0135] cc) The first antigen-binding domain binds to CTLA-4, and the second antigen-binding domain binds to GITR;
[0136] dd) The first antigen-binding domain binds to CTLA-4, and the second antigen-binding domain binds to CD107a;
[0137] ee) The first antigen-binding domain binds to CTLA-4, and the second antigen-binding domain binds to NKp46; or
[0138] ff) A complex in which the first antigen-binding domain binds to ICOS and the second antigen-binding domain binds to TNFR2.
[0139] Embodiment 99. A complex in any one of Embodiments 81 to 98, wherein the modified IL-2 binds to human IL-2R with an affinity that is at least 2, 3, 4, 5, 6, 7, 8, 9, at least 10, at least 20, at least 30, at least 50, or at least 100 times lower than the affinity of human wild-type IL-2 to IL-2R.
[0140] Embodiment 100. A pharmaceutical composition comprising a polypeptide of any one of Embodiments 1 to 80 or a complex of any one of Embodiments 81 to 99 and a pharmaceutically acceptable carrier.
[0141] Embodiment 101. Isolated nucleic acid encoding a polypeptide of any one of Embodiments 1 to 80 or a complex of any one of Embodiments 81 to 99.
[0142] Embodiment 102. An expression vector comprising the nucleic acid of Embodiment 101.
[0143] Embodiment 103. Isolated host cell comprising the nucleic acid of Embodiment 101 or the expression vector of Embodiment 102.
[0144] Embodiment 104. An isolated host cell expressing a polypeptide of any one of Embodiments 1 to 80 or a complex of any one of Embodiments 81 to 99.
[0145] Embodiment 105. A method for preparing a polypeptide of any one of Embodiments 1 to 80 or a complex of any one of Embodiments 81 to 99, comprising the step of incubating a host cell of Embodiment 103 or Embodiment 104 under conditions suitable for expressing a polypeptide or a complex.
[0146] Embodiment 106. The method of Embodiment 105, further comprising the step of isolating a polypeptide or complex.
[0147] Embodiment 107. A method for increasing CD4+ and / or CD8+ T cell proliferation, comprising the step of contacting T cells with a polypeptide of any one of Embodiments 1 to 80 or a complex of any one of Embodiments 81 to 99.
[0148] Embodiment 108. The method of Embodiment 107, wherein the CD4+ and / or CD8+ T cells are in vitro.
[0149] Embodiment 109. The method of Embodiment 107, wherein the CD4+ and / or CD8+ T cells are in vivo.
[0150] Embodiment 110. A method in any one of Embodiments 107 to 109, wherein the increase is at least 1.5 times, at least 2 times, at least 3 times, or at least 5 times.
[0151] Embodiment 111. A method for increasing NK cell proliferation, comprising the step of contacting NK cells with a polypeptide of any one of Embodiments 1 to 80 or a complex of any one of Embodiments 81 to 99.
[0152] Example 112. A method in which, in Example 111, the increase is at least 1.5 times, at least 2 times, at least 3 times, or at least 5 times.
[0153] Embodiment 113. A method for treating cancer comprising the step of administering a pharmaceutically effective amount of a polypeptide of any one of Embodiments 1 to 80, a complex of any one of Embodiments 81 to 99, or a pharmaceutical composition of Embodiment 100 to a subject having cancer.
[0154] Example 114. In Example 113, the cancer is basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; ocular cancer; head and neck cancer; gastric cancer; digestive system cancer; glioblastoma; hepatocarcinoma; liver tumor; neoplasm in situ; kidney or renal cancer; laryngeal cancer; liver cancer; lung cancer; small cell lung cancer; non-small cell lung cancer; adenocarcinoma of the lung; squamous cell carcinoma of the lung; melanoma; multiple myeloma; neuroblastoma; oral cancer; ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell carcinoma; gastric cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; A method selected from vulvar cancer; lymphoma; Hodgkin lymphoma; non-Hodgkin lymphoma; B-cell lymphoma; low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-cutting cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-associated lymphoma; Waldenstrom macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; and chronic myeloblastic leukemia.
[0155] Embodiment 115. A method according to Embodiment 113 or Embodiment 114, further comprising the step of administering an additional therapeutic agent.
[0156] Example 116. The method of Example 115, wherein the additional therapeutic agent is an anticancer agent.
[0157] Embodiment 117. The method of Embodiment 116, wherein the anticancer agent is selected from chemotherapy agents, anticancer biological agents, radiation therapy, CAR-T therapy, and oncolytic viruses.
[0158] Embodiment 118. The method of Embodiment 116 or Embodiment 117, wherein the additional therapeutic agent is an anticancer biological agent.
[0159] Embodiment 119. The method of Embodiment 118, wherein the anticancer biological agent is an agent that inhibits PD-1 and / or PD-L1.
[0160] Embodiment 120. The method of Embodiment 118, wherein the anticancer biological agent is a agent that inhibits VISTA, gpNMB, B7H3, B7H4, HHLA2, CTLA4, or TIGIT.
[0161] Embodiment 121. A method in which, in any one of Embodiments 116 to 120, the anticancer agent is an antibody.
[0162] Embodiment 122. The method of Embodiment 118, wherein the anticancer biological agent is a cytokine.
[0163] Embodiment 123. The method according to Embodiment 116, wherein the anticancer agent is a CAR-T therapy.
[0164] Example 124. In Example 116, the anticancer agent is an oncolytic virus.
[0165] Embodiment 125. A method in any one of embodiments 113 to 124, further comprising tumor resection and / or radiation therapy. Brief explanation of the drawing
[0166] Figures 1a–1h show schematic diagrams of various IL-2 fusion protein formats. Figure 1a shows IL-2 attached to the N-terminus of a heteromeric knob-in-hole IgG1 Fc. Figure 1b shows IL-2 attached to the C-terminus of a heteromeric IgG1 Fc of a single-domain antibody. Figures 1c–1e show IL-2 attached to one VHH (Figure 1e), two identical VHHs (Figure 1c), or two different VHHs (Figure 1d). Figure 1f shows IL-2 attached to the C-terminus of a homomeric heavy chain constant region of a conventional antibody. Figure 1g shows IL-2 attached to the C-terminus of a heteromeric heavy chain constant region of a conventional antibody. Figure 1h shows IL-2 fused to the C-terminus of a heteromeric scFv antibody. Figures 2a-2c show the binding of IL-2 fusion proteins, comprising wild-type IL-2 (Figure 2a) or modified IL-2 (Figures 2a-2c) fused to the N-terminus of heteromeric Fc as shown in Figure 1a, to 293F cells transiently transfected with various combinations of IL-2 receptors (CD25, CD122, and CD132), as measured by flow cytometry. "UT 293F" represents untransfected 293F cells. Figures 3a-3b show the binding of a fusion protein containing wild-type IL-2 or modified IL-2 fused to the N-terminus of a heteromeric Fc as shown in Figure 1a, for 293F cells transiently transfected with CD25 and CD122 as measured by flow cytometry. Figures 4a-4b show the binding of a fusion protein comprising wild-type IL-2 or modified IL-2 fused to the N-terminus of a heteromeric Fc as shown in Figure 1a, for 293F cells transiently transfected with CD122 and CD132 or CD25, CD122, and CD132, as measured by flow cytometry. Figures 5a-5b show the binding of a fusion protein containing wild-type IL-2 or modified IL-2 fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc as shown in Figure 1b, to resting and activated CD4+ T cells as measured by flow cytometry. "Isotype control" represents a control protein that does not contain IL-2. Figures 6a-6b show the binding of a fusion protein comprising wild-type IL-2 or modified IL-2 fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc as shown in Figure 1b, for enriched regulatory T cells (Treg, Figure 6a), induced regulatory T cells (induced Treg, Figure 6b), and enriched responder CD4+ T cells (Tresp, Figure 6c), as measured by flow cytometry. Figures 7a–7d show the activity of a fusion protein containing wild-type IL-2 or modified IL-2 fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc as shown in Figure 1b on resting CD4+ and CD8+ T cells. Proliferation (Figures 7a and 7c) and CD71 levels (Figures 7b and 7d) were measured. Figures 7e–7f show the activity of wild-type IL-2 or modified IL-2 fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc as shown in Figure 1b on resting CD4+ and CD8+ T cells, as measured by flow cytometry detection of intracellular phosphorylated STAT5 levels. "Isotype" indicates a control protein that does not contain IL-2. Figures 8a-8b show proliferation and CD25 levels as markers of activation of enriched Treg after 7 days of treatment with a fusion protein containing wild-type IL-2 or modified IL-2 fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc as shown in Figure 1b. Figures 9a–9d show the activity and binding of pembrolizumab, an analog of pembrolizumab having IL-2-RAS fused to the heavy chain C-terminus as shown in Figure 1f, and IL-2-RAS alone (Figures 9c and 9d) on CD8+ and CD4+ T cells. Activity on CD8+ (Figure 9a) and CD4+ (Figure 9b) T cells was measured by flow cytometry detection with CellTrace™ Violet. The degree of binding to CD8+ T cells (Figure 9c) and CD4+ T cells (Figure 9d) was measured by flow cytometry. Figures 10a-10d show the dependence of the induction of CD8+ and CD4+ T cell proliferation on IL-2. The effects of pembrolizumab, untargeted IL-2-RAS, and an analog of pembrolizumab with IL-2-RAS fused to the heavy chain C-terminus as shown in Figure 1f on CD8+ (Figures 10a and 10c) or CD4+ (Figures 10b and 10d) T cell proliferation that is not pre-blocked (Figures 10a and 10b) or pre-blocked with saturated concentrations of pembrolizumab (Figures 10c and 10d) are shown. Figure 11 shows the recovery of CD4+ T responder (Tresp) cell proliferation by an analog of pembrolizumab having IL-2-RAS fused to the heavy chain C-terminus as shown in Figure 1f, as well as IL-2-RAS fused to the C-terminus of untargeted VHH as shown in Figure 1b and wild-type IL-2 fused to the C-terminus of untargeted VHH as shown in Figure 1b. Tresp proliferation was induced by CD3 engagement (Tresp + beads) and then inhibited using autoregulatory T cells (Treg). The "Tresp + beads" line shows basal Tresp cell proliferation with CD3 engagement in the absence of Treg cells. The "ab-free" line shows basal Tresp cell proliferation with CD3 engagement in the presence of Treg cells. Figures 12a-12b show the trans-activation of T cells by plate-bound untargeted wild-type IL-2 ("IL-2 WT") or IL-2-RAS fused to the C-terminus of untargeted VHH as shown in Figure 1b. T cell activation was measured by flow cytometry detection of intracellular phosphorylated STAT5 levels. Responses of CD8+ T cells (Figure 12a) and CD4+ T cells (Figure 12b) are shown. Figures 13a-13i show the activity and binding of fusion proteins comprising IL-2-RAS fused to the C-terminus of a heterodimeric scFv antibody targeting NKp46 as shown in Figure 1h, a heterodimeric scFv antibody targeting NKp46 alone, and wild-type IL-2 or IL-2-RAS fused to the C-terminus of a non-targeted VHH linked to a heterodimeric Fc as shown in Figure 1b, on NK cells, CD8+ T cells, and CD4+ T cells. The proliferation of NK cells (Figure 13a), CD8+ T cells (Figure 13b), and CD4+ T cells (Figure 13c), and the pSTAT levels of NK cells (Figure 13d), CD8+ T cells (Figure 13e), and CD4+ T cells (Figure 13f) were measured by flow cytometry. The binding of the indicated polypeptide to NK cells (Fig. 13g), CD8+ T cells (Fig. 13h), and CD4+ T cells (Fig. 13i) was also measured by flow cytometry. Figures 14a-14h show the activity and binding on CD8+ or CD4+ T cells of IL-2-RAS fused to the C-terminus of an anti-LAG3 heteromeric conventional antibody (MAb) as shown in Figure 1g, IL-2-RAS fused to the C-terminus of an anti-LAG3 VHH having a heteromeric Fc as shown in Figure 1b, IL-2-RAS fused to the C-terminus of an untargeted VHH as shown in Figure 1b, wild-type IL-2 fused to the C-terminus of an untargeted heteromeric Fc as shown in Figure 1b, or LAG3-targeted MAb or LAG3-targeted VHH-Fc molecules without IL-2. The expression of proliferation and activation markers CD25 (Figs. 14c and 14d) and CD71 (Figs. 14e and 14f) on CD8+ T cells (Figs. 14a) and CD4+ T cells (Figs. 14b) was measured by flow cytometry. Figs. 14g and 14h show binding to pre-activated CD8+ T cells (Fig. 14g) and CD4+ T cells (Fig. 14h). Figure 15 shows the activity of a fusion protein containing the indicated modified IL-2 fused to the C-terminus of VHH having a heteromeric Fc as shown in Figure 1b on HEK-Blue IL-2 reporter cells that do not express the target antigen of VHH and therefore rely only on the binding of modified IL-2 to the IL-2 receptor overexpressed for the induction of the reporter gene. The activity of secreted embryonic alkaline phosphatase expressed in response to IL-2 receptor-mediated induction of pSTAT5 signaling in reporter cells was measured. Specific details for implementing the invention
[0167] The embodiments provided herein relate to polypeptides containing modified IL-2 that regulate T cell activity and their use in various methods for treating cancer.
[0168] Definition and various Implementation example
[0169] The section titles used herein are for organizational purposes only and should not be interpreted as limiting the subject matter described.
[0170] All references cited herein, including patent applications, patent publications, and Genbank registration numbers, are incorporated herein by reference as specifically and individually indicated that each individual reference is included by reference in its entirety.
[0171] The techniques and procedures described or mentioned herein are generally well understood, for example, in the literature [Sambrook et al. , Molecular Cloning: A Laboratory Manual 3rd. edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (FM Ausubel, et al. eds ., (2003)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (MJ MacPherson, BD Hames and GR Taylor eds . (1995)), Harlow and Lane, eds . (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (RI Freshney, ed. (1987)); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J. E. Cellis, ed. , 1998) Academic Press; Animal Cell Culture (R. I. Freshney), ed ., 1987); Introduction to Cell and Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press; Cell and Tissue Culture Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, eds .); Gene Transfer Vectors for Mammalian Cells (J. M. Miller and M. P. Calos, eds ., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al. , eds ., 1994); Current Protocols in Immunology (J. E. Coligan et al. , eds ., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C. A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., ed. , IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds ., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and JD Capra, eds ., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (VT DeVita et al. , eds ., JB Lippincott Company, 1993)]; and is commonly used by those skilled in the art using general methods, such as the widely used method described in the updated version thereof.
[0172] Unless otherwise defined, scientific and technical terms used in connection with this disclosure shall have the meanings generally understood by those skilled in the art. Additionally, unless otherwise required by the context or explicitly indicated, singular terms shall include the plural, and plural terms shall include the singular. In the event of any conflict of definitions between various sources or references, the definitions provided herein shall prevail.
[0173] Generally, the residue numbers in immunoglobulin heavy chains are [Kabat et al ., Sequences of Proteins of Immunological InterestIt is the number of the EU index as in , 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). “EU index as in kabat” refers to the residue number of the human IgG1 EU antibody.
[0174] The embodiments of the invention described herein are understood to include "consisting of" and / or "essentially consisting of" the embodiments. As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. The use of the term "or" herein does not imply that alternatives are mutually exclusive.
[0175] In this application, the use of "or" means "and / or" unless explicitly stated or understood by those skilled in the art. In the context of multiple dependent claims, the use of "or" refers to two or more preceding independent or dependent claims.
[0176] The phrases “reference sample,” “reference cell,” or “reference tissue” refer to a sample having at least one known feature that can be used as a comparison with a sample having at least one unknown feature. In some embodiments, the reference sample may be used as a positive or negative indicator. The reference sample may be used to establish, for example, levels of protein and / or mRNA present in healthy tissue in contrast to levels of protein and / or mRNA present in the sample having the unknown feature. In some embodiments, the reference sample is derived from the same subject but from a part of the subject different from the part being tested. In some embodiments, the reference sample is derived from tissue surrounding or adjacent to the cancer. In some embodiments, the reference sample is not derived from the subject being treated, but is a sample from a subject known to have or not have the disorder in question (e.g., a specific cancer or T-cell related disorder). In some embodiments, the reference sample is derived from the same subject but from a point in time prior to the onset of cancer in the subject. In some embodiments, the reference sample is derived from a positive cancer sample from the same or different subject. Where a negative reference sample is used for comparison, the expression level or amount of the molecule in question within the negative reference sample will represent a level that a person skilled in the art would understand, considering the present disclosure, to be absent or at a low level of the molecule. Where a positive reference sample is used for comparison, the expression level or amount of the molecule in question within the positive reference sample will represent a level that a person skilled in the art would recognize, considering the present disclosure, to be present of the molecule.
[0177] The terms “benefit,” “clinical benefit,” “responsiveness,” and “therapeutic responsiveness,” as used herein in the context of obtaining benefit from the administration of a therapeutic agent or responding to the administration of a therapeutic agent, may be measured by evaluating various endpoints of disease progression, such as some degree of inhibition, including: deceleration and complete cessation; reduction in the number of disease episodes and / or symptoms; reduction in lesion size; inhibition of disease cell infiltration into adjacent peripheral organs and / or tissues (i.e., reduction, deceleration, or complete cessation); inhibition of disease spread (i.e., reduction, deceleration, or complete cessation); some degree of remission of one or more symptoms associated with the disorder; length of disease-free presentation after treatment, e.g., increased progression-free survival; increased overall survival; higher response rate; and / or reduced mortality at a given time point after treatment. A “non-responsive” or “unresponsive” subject or cancer is a subject or cancer that does not meet the aforementioned qualifications to be “responsive.”
[0178] The terms "nucleic acid molecule," "nucleic acid," and "polynucleotide" may be used interchangeably and refer to polymers of nucleotides. Such polymers of nucleotides may contain natural and / or non-natural nucleotides and include, but are not limited to, DNA, RNA, and PNA. "Nucleic acid sequence" refers to a linear sequence of nucleotides contained in a nucleic acid molecule or polynucleotide.
[0179] The terms “polypeptide” and “protein” are used interchangeably to refer to polymers of amino acid residues and are not limited to minimum length. Such polymers of amino acid residues may contain natural or non-natural amino acid residues and, without limitation, include peptides, oligopeptides, dimers, trimers, and tetramers of amino acid residues. Both full-length proteins and fragments thereof are included in the definition. The term also includes post-expression modifications of polypeptides, e.g., glycosylation, sialylation, acetylation, phosphorylation, etc. Additionally, for the purposes of this disclosure, “polypeptide” refers to a protein that includes modifications such as deletions, additions, and substitutions to the natural sequence (generally naturally conserved) as long as the protein retains the desired activity. Such modifications may be intentional, such as through site-specific mutagenesis, or accidental, such as through mutations in the host producing the protein or errors resulting from PCR amplification. "Amino acid sequence" refers to a linear sequence of amino acids contained in a polypeptide or protein.
[0180] As used herein, “IL-2” or “Interleukin-2” refers to any naturally occurring mature IL-2 derived from the processing of an IL-2 precursor in a cell. Unless otherwise indicated, the term includes IL-2 from any vertebrate, including mammals, e.g., primates (e.g., humans and cynomolgus or rhesus monkeys), and rodents (e.g., mice and rats). The term also includes naturally occurring variants of IL-2, such as splice variants or allelic variants. Non-limiting exemplary human IL-2 amino acid sequences are shown, for example, in GenBank registry number NP_000577.2. See Sequence No. 1 (mature form).
[0181] As used herein, "modified IL-2" refers to a polypeptide that differs from the wild-type IL-2 amino acid sequence by substitution at at least one amino acid position.
[0182] The term "specifically binds" to an antigen or epitope is a well-known term in the art, and the method for determining such specific binding is also well-known in the art. It is said that a molecule exhibits "specific binding" or "preferential binding" when it reacts with or binds to a specific cell or substance more frequently, more quickly, for a longer duration, and / or with greater affinity than it reacts with an alternative cell or substance. An antigen-binding domain "specifically binds" or "preferentially binds" to an antigen when it binds to it with greater affinity, binding strength, more easily, and for a longer duration than it binds to other substances. For example, an sdAb or VHH-containing polypeptide that binds specifically or preferentially to an epitope is an sdAb or VHH-containing polypeptide that binds to this epitope with greater affinity, binding strength, more readily, and / or for a longer duration than it binds to other epitopes on the same target antigen or other epitopes on different target antigens. Also, reading this definition; for example, it is understood that an antigen-binding domain that binds specifically or preferentially to a first antigen may or may not bind specifically or preferentially to a second antigen. As such, "specific binding" or "preferential binding" does not necessarily require exclusive binding (though it may include it). Generally, references to binding, though not always, mean preferential binding. "Specificity" refers to the ability of a binding protein to bind selectively to an antigen.
[0183] As used herein, with respect to the activity of IL-2, the term "regulate" refers to a change in the activity of IL-2. In some embodiments, "regulate" refers to an increase in IL-2 activity.
[0184] As used herein, the term “epitope” refers to a site on a target molecule (e.g., an antigen, such as a protein, nucleic acid, carbohydrate, or lipid) to which an antigen-binding molecule (e.g., a polypeptide containing an antigen-binding domain) binds. Epitopes often comprise chemically active surface groups of molecules, such as amino acids, polypeptides, or sugar side chains, and possess specific charge characteristics as well as three-dimensional structural features. Epitopes can be formed from both adjacent and / or juxtaposed non-adjacent residues (e.g., amino acids, nucleotides, sugars, lipid moieties) of the target molecule. Epitopes formed from adjacent residues (e.g., amino acids, nucleotides, sugars, lipid moieties) are typically retained upon exposure to a denaturing solvent, whereas epitopes formed by tertiary folding are typically lost upon treatment with a denaturing solvent. The epitope may, without limitation, comprise at least 3, at least 5, or 8 to 10 residues (e.g., amino acids or nucleotides). In some embodiments, the epitope is less than 20 residues (e.g., amino acids or nucleotides) in length, less than 15 residues, or less than 12 residues. Two antibodies may bind to the same epitope within the antigen if they exhibit competitive binding to the antigen. In some embodiments, the epitope may be identified by a specific minimum distance to a CDR residue on the antigen-binding molecule. In some embodiments, the epitope may be identified by said distance and is further limited to residues involved in binding (e.g., hydrogen bonding) between residues of the antigen-binding molecule and antigen residues. The epitope may also be identified by various scans, for example, an alanine or arginine scan may indicate one or more residues with which the antigen-binding molecule can interact. Unless explicitly indicated, a set of residues as an epitope does not exclude other residues that become part of the epitope for a specific antigen-binding domain or molecule.Rather, the existence of such a set specifies a minimum series (or set of species) of epitopes. Thus, in some embodiments, the set of residues identified as epitopes specifies a minimum epitope of relevance to the antigen rather than an exclusive list of residues for epitopes on the antigen.
[0185] A “nonlinear epitope” or “stereotypical epitope” comprises non-adjacent polypeptides, amino acids, and / or sugars within an antigenic protein to which an antigen-binding molecule specific to the epitope (e.g., a polypeptide containing an antigen-binding domain) binds. In some embodiments, at least one of the residues will not be adjacent to another mentioned residue of the epitope, but one or more of the residues may also be adjacent to other residues.
[0186] A “linear epitope” comprises adjacent polypeptides, amino acids, and / or sugars within an antigenic protein to which an antigen-binding molecule specific to the epitope (e.g., a polypeptide containing an antigen-binding domain) binds. It should be noted that in some embodiments, not all residues within the linear epitope need to be directly bound (or involved in binding) by the antigen-binding molecule. In some embodiments, the linear epitope may be derived from an immunization using a peptide effectively composed of the sequence of the linear epitope, or from a structural section of the protein relatively isolated from the rest of the protein (whereby the antigen-binding molecule can at least primarily interact) along with only the sequence section.
[0187] The terms “antibody” and “antigen-binding molecule” are used interchangeably in the broadest sense and, without limitation, include conventional antibodies (typically comprising at least one heavy chain and at least one light chain), single-domain antibodies (sdAb, typically comprising only one chain similar to a heavy chain), VHH-containing polypeptides (at least one heavy chain single antibody variable domain, or polypeptides containing VHH), and various polypeptides comprising an antigen-binding domain, comprising a fragment of any of the foregoing that exhibits the desired antigen-binding activity. In some embodiments, the antibody comprises a dimerization domain. Such dimerization domains, without limitation, comprise a heavy chain constant domain (comprising CH1, a hinge, CH2, and CH3, wherein CH1 is typically paired with a light chain constant domain CL, while the hinge mediates dimerization) and an Fc region (comprising a hinge, CH2, and CH3, wherein the hinge mediates dimerization). The term antibody also, but not limitedly, includes chimeric antibodies, humanized antibodies, and antibodies of various species, such as camelid (including llama), shark, mouse, human, cynomolgus monkey, etc.
[0188] The terms “single-domain antibody” and “sdAb” are used interchangeably herein to refer to antibodies having a single monomeric domain, typically a heavy chain (or VHH), without a light chain.
[0189] As used herein, the terms “VHH,” “VHH domain,” or “VHH antigen-binding domain” refer to the antigen-binding portion of a single-domain antibody, such as a camelid antibody or a shark antibody. In some embodiments, VHH comprises three CDRs and four framework regions designated as FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In some embodiments, VHH may comprise only partial FR1 and / or FR4 as long as it substantially maintains antigen binding and specificity, or may be cleaved at the N-terminus or C-terminus to lack one or both of the framework regions.
[0190] The term "VHH-containing polypeptide" refers to a polypeptide comprising at least one VHH domain. In some embodiments, the VHH polypeptide comprises two, three, or four or more VHH domains, and each VHH domain may be identical or different. In some embodiments, the VHH-containing polypeptide comprises an Fc region. In some of these embodiments, the VHH polypeptide may form a dimer. Non-limiting structures of the VHH-containing polypeptide include VHH1-Fc, VHH1-VHH2-Fc, and VHH1-VHH2-VHH3-Fc, where VHH1, VHH2, and VHH3 may be identical or different. In some embodiments of these structures, one VHH may be linked to another VHH by a linker, or one VHH may be linked to Fc by a linker. In some of these embodiments, the linker comprises 1 to 20 amino acids, preferably composed mainly of glycine and, optionally, serine. In some embodiments, if the VHH-containing polypeptide contains Fc, it forms a dimer. Thus, the structure VHH1-VHH2-Fc is considered tetravalent when forming a dimer (i.e., the dimer has four VHH domains). Similarly, the structure VHH1-VHH2-VHH3-Fc is considered hexavalent when forming a dimer (i.e., the dimer has six VHH domains).
[0191] The term "monoclonal antibody" refers to a substantially homogeneous population of antibodies (including sdAb or VHH-containing polypeptides), meaning that the individual antibodies constituting the population are identical except for possible naturally occurring mutations that may be present in small amounts. Monoclonal antibodies are highly specific and are directed toward a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which typically contain different antibodies for different determinants (epitopes), each monoclonal antibody is directed toward a single determinant on the antigen. Therefore, samples of monoclonal antibodies can bind to the same epitope on the antigen. The modifier "monoclonal" indicates the characteristic of antibodies obtained from a substantially homogeneous population of antibodies and should not be interpreted as requiring the production of antibodies by any specific method. For example, monoclonal antibodies may be produced by the hybridoma method first described in the literature [Kohler and Milstein, 1975, Nature 256:495], or by the recombinant DNA method as described in U.S. Patent No. 4,816,567. Monoclonal antibodies can also be produced, for example, in the literature [McCafferty et al It can be isolated from a phage library generated using the technique described in [., 1990, Nature 348:552-554].
[0192] The term "CDR" represents a complementarity determination region as defined by at least one identification method to those skilled in the art. In some embodiments, the CDR may be defined according to any of the Chotia numbering scheme, the Kavat numbering scheme, a combination of Kavat and Chotia, the AbM definition, and / or the contact definition. VHH includes three CDRs designated as CDR1, CDR2, and CDR3.
[0193] As used herein, the term "heavy chain invariant region" refers to at least three heavy chain invariant domains, C H 1, hinge, CH 2, and C H It refers to a region containing 3. Of course, deletions and modifications that do not alter the function within the domain are included within the scope of the term "heavy chain constant region" unless otherwise specified. Non-limiting exemplary heavy chain constant regions include γ, δ, and α. Non-limiting exemplary heavy chain constant regions also include ε and μ. Each heavy chain constant region corresponds to an antibody isotype. For example, an antibody containing a γ constant region is an IgG antibody, an antibody containing a δ constant region is an IgD antibody, and an antibody containing an α constant region is an IgA antibody. Additionally, an antibody containing a μ constant region is an IgM antibody, and an antibody containing an ε constant region is an IgE antibody. Specific isotypes may be further subdivided into subcategories. For example, IgG antibodies include, non-limitingly, IgG1 (containing a γ1 constant region), IgG2 (containing a γ2 constant region), IgG3 (containing a γ3 constant region), and IgG4 (containing a γ4 constant region); IgA antibodies include, but are not limited to, IgA1 (including α1 constant region) and IgA2 (including α2 constant region) antibodies; and IgM antibodies include, but are not limited to, IgM1 and IgM2.
[0194] As used herein, the “Fc region” refers to a portion of a heavy chain constant region comprising CH2 and CH3. In some embodiments, the Fc region comprises a hinge, CH2, and CH3. In various embodiments, where the Fc region comprises a hinge, the hinge mediates dimerization between two Fc-containing polypeptides. The Fc region may be a region of any antibody heavy chain constant region isotype discussed herein. In some embodiments, the Fc region is IgG1, IgG2, IgG3, or IgG4.
[0195] As used herein, the "acceptor human framework" refers to a heavy chain variable domain (V) derived from the human immunoglobulin framework or the human common framework as discussed herein. H It is a framework containing the amino acid sequence of the framework. A recipient human framework derived from the human immunoglobulin framework or the human common framework may contain the same amino acid sequence, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is less than 10, or less than 9, or less than 8, or less than 7, or less than 6, or less than 5, or less than 4, or less than 3 across all human frameworks within a single antigen-binding domain such as VHH.
[0196] "Affinity" refers to the strength of the total sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or VHH-containing polypeptide) and its binding partner (e.g., an antigen). The affinity or apparent affinity of molecule X for its partner Y is generally given by the dissociation constant (K), respectively. D ) or K D - apparent Affinity can be indicated by conventional methods known in the art (e.g., ELISA K) including those described herein. D It can be measured by KinExA, flow cytometry, and / or surface plasmon resonance devices. These methods include, but are not limited to, BIAcore®, Octet®, or flow cytometry.
[0197] As used herein, the term "K D " refers to the equilibrium dissociation constant of the antigen-binding molecule / antigen interaction. The term "K D If " is used in this institution, it is K D and K D - apparent Includes
[0198] In some embodiments, K of the antigen-binding molecule D is measured by flow cytometry using antigen-expressing cell lines and fitting the average fluorescence measured at each antibody concentration to a non-linear 1-site coupling equation (PRISM Software GraphPad). In some of these embodiments, K D is K D-apparent am.
[0199] The term "biological activity" refers to any one or more biological properties of a molecule (whether naturally occurring, such as found in vivo, or provided or made possible by recombination means). Biological properties include, but are not limited to, ligand binding, induction or increase of cell proliferation (e.g., T cell proliferation), and induction or increase of cytokine expression.
[0200] As used herein, the term “IL-2 activity” or “biological activity” of IL-2 comprises at least one of any biological effect or biologically relevant characteristic of IL-2. In some embodiments, IL-2 activity includes the ability of IL-2 to induce T cell proliferation and / or activate natural killer (NK) cells. Non-limiting exemplary IL-2 activities include increased pSTAT5 expression, CD4 + and / or CD8 + Increased T cell proliferation, increased CD71 expression on T cells, and CD4 + and CD8 + It includes a reduction in the inhibitory activity of Treg cells on T cell activation and proliferation.
[0201] "Agent" or "activating" antibodies (e.g., sdAb or VHH-containing polypeptides) are intended to increase and / or activate the biological activity of a target antigen. In some embodiments, the agonist antibody binds to the antigen and increases its biological activity by at least about 20%, 40%, 60%, 80%, 85% or more.
[0202] "Antagonist," "blocker," or "neutralizing" antibody reduces and / or inactivates the biological activity of a target antigen. In some embodiments, the neutralizing antibody binds to the antigen and reduces its biological activity by at least about 20%, 40%, 60%, 80%, 85%, 90%, 95%, 99% or more.
[0203] "Affinity-mature" VHH-containing polypeptides refer to VHH-containing polypeptides that have one or more changes in one or more CDRs compared to parent VHH-containing polypeptides that do not have these changes, and these changes improve the affinity of the VHH-containing polypeptide for the antigen.
[0204] As used herein, “humanized VHH” refers to a VHH in which one or more framework regions are substantially replaced by human framework regions. In some cases, specific framework region (FR) residues of human immunoglobulin are replaced by corresponding non-human residues. Additionally, the humanized VHH may include residues that are not found in the original VHH or human framework sequence but are included to further improve and optimize the performance of the VHH or VHH-containing polypeptide. In some embodiments, the humanized VHH-containing polypeptide includes a human Fc region. As is understood, the humanized sequence may be identified by its primary sequence and does not necessarily represent the process of antibody generation.
[0205] The "functional Fc region" possesses "effector functions" of the natural sequence Fc region. Exemplary "effector functions" include Fc receptor binding; Clq binding and complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B-cell receptors); and B-cell activation. These effector functions generally require the Fc region to be combined with a binding domain (e.g., antibody variable domain) and can be evaluated using various assays.
[0206] The "natural sequence Fc region" contains an amino acid sequence identical to the amino acid sequence of the Fc region found in nature. The natural sequence human Fc region includes the natural sequence human IgG1 Fc region (non-A and A allotypes); the natural sequence human IgG2 Fc region; the natural sequence human IgG3 Fc region; and the natural sequence human IgG4 Fc region, as well as their naturally occurring variants.
[0207] The “variant Fc region” comprises an amino acid sequence that differs from that of the natural sequence Fc region due to at least one amino acid modification. In some embodiments, the “variant Fc region” comprises an amino acid sequence that differs from that of the natural sequence Fc region due to at least one amino acid modification but retains at least one effector of the natural sequence Fc region. In some embodiments, the variant Fc region has at least one amino acid substitution compared to the natural sequence Fc region or the Fc region of the parent polypeptide, for example, about 1 to about 10 amino acid substitutions in the natural sequence Fc region or the Fc region of the parent polypeptide, and preferably about 1 to about 5 amino acid substitutions. In some embodiments, the variant Fc region of the present invention will have at least about 80% sequence identity with the natural sequence Fc region and / or the Fc region of the parent polypeptide, at least about 90% sequence identity with it, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity with it.
[0208] "Fc receptor" or "FcR" describes a receptor that binds to the Fc region of an antibody. In some embodiments, FcγR is a natural human FcR. In some embodiments, FcR is a receptor of the FcγRI, FcγRII, and FcγRIII subclasses that bind to an IgG antibody (gamma receptor) and include allelic variants and selectively spliced forms of the receptor. The FcγRII receptor includes FcγRIIA (an "activating receptor") and FcγRIIB ("inhibiting receptor"), which have different similar amino acid sequences, mainly in their cytoplasmic domains. The activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activating motif (ITAM) within its cytoplasmic domain, and the inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) within its cytoplasmic domain (see, e.g., Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcR is, for example, [Ravetch and Kinet, Annu Rev. Immunol 9:457-92 (1991); Capel et al ., Immunomethods 4:25-34 (1994); and de Haas et al ., J. Lab. Clin . Med . This is reviewed in [126:330-41 (1995)]. Other FcRs, including those to be identified in the future, are included herein by the term "FcR". For example, the term "Fc receptor" or "FcR" also refers to the transmission of maternal IgG to the fetus (Guyer et al ., J. Immunol . 117:587 (1976) and Kim et al ., J. ImmunolThis includes the neonatal receptor FcRn, which is responsible for the homeostatic regulation of immunoglobulins (e.g., . 24:249 (1994)). Methods for measuring binding to FcRn are known (e.g., Ghetie and Ward, Immunol Today 18(12):592-598(1997); Ghetie et al ., Nature Biotechnology , 15(7):637-640(1997); Hinton et al. , J. Biol . Chem . 279(8):6213-6216(2004); WO No. 2004 / 92219 (Hinton et al. ) reference).
[0209] As used herein, the terms “substantially similar” or “substantially identical” indicate a sufficiently high similarity between two or more numerical values such that a person skilled in the art considers the difference between two or more values to have little or no biological and / or statistical significance within the context of the biological characteristic measured by said values. In some embodiments, two or more substantially similar values differ by about 5%, 10%, 15%, 20%, 25%, or 50% or less.
[0210] A polypeptide “variant” means a biologically active polypeptide having at least about 80% amino acid sequence identity with the natural sequence polypeptide after aligning sequences and introducing gaps where necessary to achieve maximum percentage sequence identity and not considering any conservative substitutions as part of the sequence identity. Such variants include, for example, polypeptides in which one or more amino acid residues are added or deleted at the N- or C-terminus of the polypeptide. In some embodiments, the variant will have at least about 80% amino acid sequence identity. In some embodiments, the variant will have at least about 90% amino acid sequence identity. In some embodiments, the variant will have at least about 95% amino acid sequence identity with the natural sequence polypeptide.
[0211] As used herein, “percentage (%) amino acid sequence identity” and “homology” for a peptide, polypeptide, or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence identical to the amino acid residues in a specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps where necessary to achieve maximum percentage sequence identity, and after not considering any conservative substitutions as part of the sequence identity. Alignment for determining percentage amino acid sequence identity may be achieved in various ways within the scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNASTAR) software. Those skilled in the art may determine appropriate parameters for measuring alignment, including any algorithm necessary to achieve maximum alignment over the entire length of the sequences being compared.
[0212] Amino acid substitutions may, without limitation, involve replacing one amino acid within the polypeptide with another amino acid. Exemplary substitutions are shown in Table 1. Amino acid substitutions may be introduced into antibodies of interest and screened for desired activities, e.g., maintained / improved antigen or receptor binding, reduced antigen or receptor binding, reduced immunogenicity, or improved ADCC or CDC.
[0213]
[0214] Amino acids can be classified according to common side chain characteristics:
[0215] (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
[0216] (2) Neutral hydrophobicity: Cys, Ser, Thr, Asn, Gln;
[0217] (3) Acids: Asp, Glu;
[0218] (4) Basics: His, Lys, Arg;
[0219] (5) Residues affecting chain orientation: Gly, Pro;
[0220] (6) Aromatic: Trp, Tyr, Phe.
[0221] Non-conservative substitution will involve changing a member of one of these classes into another class.
[0222] The term “vector” is used to describe a cloned polynucleotide that can be replicated in a host cell or a polynucleotide that can be engineered to contain a polynucleotide. A vector may include one or more of the following elements: a replication origin, one or more regulatory sequences that regulate the expression of the polypeptide of interest (e.g., a promoter and / or enhancer), and / or one or more selection marker genes (e.g., antibiotic resistance genes and genes that can be used for colorimetric analysis, e.g., β-galactosidase). The term “expression vector” refers to a vector used to express the polypeptide of interest in a host cell.
[0223] "Host cell" refers to a cell that may or was a recipient of a vector or isolated polynucleotide. The host cell may be a prokaryotic or eukaryotic cell. Exemplary eukaryotic cells include mammalian cells, e.g., primate or non-primate animal cells; fungal cells, e.g., yeast; plant cells; and insect cells. Non-limiting exemplary mammalian cells include, non-limitingly, NSO cells, PER.C6 ® Includes Crucells, and 293F and CHO cells, and derivatives thereof, such as 293-6E, CHO-DG44, CHO-K1, CHO-S, and CHO-DS cells. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or genomic DNA complement) to the original parent cell due to natural, accidental, or intentional mutations. Host cells include cells transfected in vivo with the polynucleotide(s) provided herein.
[0224] As used herein, the term "isolated" refers to a molecule separated from at least some of the components typically found in nature or produced. For example, a polypeptide is referred to as "isolated" when it is separated from at least some of the components of the cell in which it was produced. If the polypeptide is secreted by the cell after expression, physically separating the supernatant containing the polypeptide from the cell that produced it is considered "isolating" the polypeptide. Similarly, a polynucleotide is referred to as "isolated" when it is typically found in nature, or, for example, in the case of an RNA polynucleotide, when it is part of a larger polynucleotide (e.g., genomic DNA or mitochondrial DNA in the case of a DNA polynucleotide) separated from at least some of the components of the cell in which it was produced. Thus, a DNA polynucleotide contained in a vector inside a host cell may be referred to as "isolated."
[0225] The terms “individual” and “subject” are used interchangeably herein to refer to animals; for example, mammals. In some embodiments, methods for treating mammals are provided, including, but not limited to, humans, rodents, primates, cats, dogs, horses, cattle, pigs, sheep, goats, mammalian laboratory animals, mammalian farm animals, mammalian sports animals, and mammalian pets. In some embodiments, “individual” or “subject” refers to an individual or subject requiring treatment for a disease or disorder. In some embodiments, the subject receiving treatment may be a patient who specifies that the subject has been identified as having a disorder related to the treatment, or is identified as being at sufficient risk of developing a disorder.
[0226] As used herein, "disease" or "disorder" refers to a pathological condition requiring or desiring treatment.
[0227] The terms “tumor cell,” “cancer cell,” “cancer,” “tumor,” and / or “neoplasm” are used interchangeably herein unless otherwise specified and refer to cells (or cells) exhibiting uncontrolled growth and / or abnormally increased cell survival and / or inhibition of apoptosis that interferes with the normal functioning of body organs and systems. This definition includes benign and malignant cancers, polyps, hyperplasia, as well as dormant tumors or micrometastasis.
[0228] The terms “cancer” and “tumor” include solid and hematological / lymphatic cancers, and also include malignant, premature, and benign growths, such as dysplasia. Additionally, this definition includes cells having abnormal proliferation that is not hindered by the immune system (e.g., immune evasion and immune escape mechanisms) (e.g., virus-infected cells). Exemplary cancers are, without limitation: basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colorectal cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including digestive cancer); glioblastoma; hepatocarcinoma; liver tumor; neoplasm in situ; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; Lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous cell carcinoma of the lung); melanoma; multiple myeloma; neuroblastoma; oral cancer (lips, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell carcinoma; gastrointestinal cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphomas including Hodgkin and non-Hodgkin lymphomas, as well as B-cell lymphoma (including low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-rectal cell NHL; and macrolesion NHL); mantle cell lymphoma; AIDS-associated lymphoma; and Waldenström macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as nevus, edema (e.g., associated with brain tumors), and abnormal angiogenesis associated with Meig syndrome.
[0229] As used herein, the term “non-tumor cell” refers to normal cells or tissues. Exemplary non-tumor cells include, but are not limited to: T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, dendritic cells, monocytes, macrophages, epithelial cells, fibroblasts, hepatocytes, interstitial renal cells, fibroblast-like synovial cells, osteoblasts, and cells located in the breast, skeletal muscle, pancreas, stomach, ovary, small intestine, placenta, uterus, testis, kidney, lung, heart, brain, liver, prostate, colon, lymphatic organs, bone, and bone-derived mesenchymal stem cells. As used herein, the term “peripheral cell or tissue” refers to non-tumor cells that are not located near tumor cells and / or within the tumor microenvironment.
[0230] As used herein, the term “cells or tissues within the tumor microenvironment” refers to cells, molecules, extracellular matrix, and / or blood vessels surrounding or supplying tumor cells. Exemplary cells or tissues within the tumor microenvironment include, but are not limited to: tumor vascular structures; tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPCs); cancer-associated fibroblasts; perivascular cells; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen-presenting cells; T cells; regulatory T cells (Treg cells); macrophages; neutrophils; myeloid-derived suppressor cells (MDSCs); and other immune cells located in proximity to the tumor. Methods for identifying tumor cells and / or cells / tissues located within the tumor microenvironment are widely known in the art as described below.
[0231] In some embodiments, “increase” or “decrease” refers to a statistically significant increase or decrease, respectively. As will be apparent to those skilled in the art, “modification” may involve a change (which may be an increase or a decrease) in the affinity, binding strength, specificity, and / or selectivity of the target or antigen to one or more of its ligands, binding partners, partners for association in homopolymeric or heteropolymeric forms, or substrates, compared to the same conditions in which the test agent is not present; a change (which may be an increase or a decrease) in the sensitivity of the target or antigen to one or more conditions in a medium or surrounding environment (e.g., pH, ionic strength, presence of cofactors, etc.) in which the target or antigen is present (which may be an increase or a decrease); and / or may involve cell proliferation or cytokine production. This may be determined in any suitable manner depending on the relevant target and / or using any suitable assay known in itself or described herein.
[0232] As used herein, "immune response" means a cellular and / or humoral immune response sufficient to suppress or prevent the onset of a disease (e.g., cancer or cancer metastasis) or to improve its symptoms. "Immune response" may include aspects of both the innate and adaptive immune systems.
[0233] As used herein, “treatment” is an approach to obtain a beneficial or desired clinical outcome. As used herein, “treatment” includes any administration or application of a therapeutic agent for a disease in mammals, including humans. For the purposes of this disclosure, beneficial or desired clinical outcomes include, without limitation, the alleviation of one or more symptoms; a reduction in the severity of the disease; prevention or delay of the spread of the disease (e.g., metastasis, e.g., to the lungs or lymph nodes); prevention or delay of the recurrence of the disease; delay or slowing of the progression of the disease; improvement of the disease state; inhibition of the disease or disease progression; inhibition or slowing of the disease or its progression; cessation of its development; and remission (partial or total). A reduction in the pathological consequences of a proliferative disease is also included in “treatment.” The methods provided herein consider one or more of these therapeutic aspects. In the context above, the term treatment does not require 100% elimination of all aspects of the disorder.
[0234] "Improvement" means the alleviation or improvement of one or more symptoms compared to not administering the treatment. "Improvement" also includes a shortening or reduction in the duration of symptoms.
[0235] The term “anticancer agent” is used herein in its broadest sense to refer to a agent used for the treatment of one or more cancers. Exemplary classes of such agents include, but are not limited to, chemotherapy agents, anticancer biological agents (e.g., cytokines, receptor extracellular domain-Fc fusions, and antibodies), radiotherapy, CAR-T therapy, therapeutic oligonucleotides (e.g., antisense oligonucleotides and siRNA), and oncolytic viruses.
[0236] The term “biological sample” means an amount of material from a living organism or a prior organism. Such material includes, but is not limited to, blood (e.g., whole blood), plasma, serum, urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes, monocytes, other cells, organs, tissues, bone marrow, lymph nodes, and spleen.
[0237] The terms "control" or "reference" refer to a composition known not to contain the analyte (“negative control”) or known to contain the analyte (“positive control”). The positive control may contain the analyte at a known concentration.
[0238] The term “repress” or “repress” refers to the reduction or cessation of any phenotypic feature or the reduction or cessation of the occurrence, degree, or likelihood of said feature. “Reducing” or “repressing” means reducing, decreasing, or stopping the activity, function, and / or amount compared to the reference. In some embodiments, “reducing” or “repressing” means the ability to cause a total reduction of 10% or more. In some embodiments, “reducing” or “repressing” means the ability to cause a total reduction of 50% or more. In some embodiments, “reducing” or “repressing” means the ability to cause a total reduction of 75%, 85%, 90%, or 95% or more. In some embodiments, the said amount is repressed or reduced for a certain period compared to the control group during the same period.
[0239] As used herein, "delaying the development of a disease" means postponing, hindering, slowing, delaying, stabilizing, suppressing, and / or postponing the development of a disease (e.g., cancer). Such delay may be of varying lengths depending on the history of the disease and / or the individual being treated. As will be apparent to those skilled in the art, a sufficient or significant delay may include prevention in that the individual effectively does not develop the disease. For example, terminal cancer, such as the development of metastasis, may be delayed.
[0240] As used herein, “prevention” includes providing prevention regarding the occurrence or recurrence of the disease in subjects who may be susceptible to the disease but have not yet been diagnosed with the disease. Unless otherwise specified, the terms “reduction,” “inhibition,” or “prevention” do not imply or require complete prevention over all time, but only during the time being measured.
[0241] The "therapeutic effective dose" of a substance / molecule, agonist, or antagonist may vary depending on factors such as the individual's disease state, age, sex, and body weight, and the ability of the substance / molecule, agonist, or antagonist to induce the desired response in the individual. The therapeutic effective dose is also an amount of the substance / molecule, agonist, or antagonist where any toxic or harmful effect is less than the therapeutically beneficial effect. The therapeutic effective dose may be delivered in one or more administrations. The therapeutic effective dose refers to the amount effective at a given dose and for the required duration to achieve the desired therapeutic and / or prophylactic outcome.
[0242] The terms “pharmaceutical preparation” and “pharmaceutical composition” refer to a form intended to effectively enhance the biological activity of the active ingredient(s) and does not contain additional components that are unacceptably toxic to the subject to whom the preparation is to be administered. Such preparations may be sterile.
[0243] "Pharmaceuticalally acceptable carrier" refers to a non-toxic solid, semi-solid, or liquid filler, diluent, encapsulating material, formulation adjuvant, or carrier conventional in the art for use with a therapeutic agent comprising a "pharmaceutical composition" to be administered to a subject. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration used and is compatible with other components of the formulation. A pharmaceutically acceptable carrier is suitable for the formulation used.
[0244] Administration "combined" with one or more additional therapeutic agents includes simultaneous (co-occurring) and sequential administration in any order.
[0245] The term “simultaneously” is used herein to refer to the administration of two or more therapeutic agents, wherein at least part of the administration overlaps in time, or the administration of one therapeutic agent falls within a shorter time compared to the administration of another therapeutic agent, or the therapeutic effects of the two agents overlap for at least a certain period.
[0246] The term "sequentially" is used herein to refer to the administration of two or more therapeutic agents that do not overlap in time or have overlapping therapeutic effects.
[0247] As used herein, "together" refers to the administration of one additional mode of treatment to another mode of treatment. As such, "together" refers to the administration of one mode of treatment before, during, or after the administration of another mode of treatment to an individual.
[0248] The term "package insert" is used to refer to instructions customarily included in the commercial packaging of therapeutic products, which contain information regarding indications, dosage, administration, combination therapy, contraindications, and / or warnings concerning the use of such therapeutic products.
[0249] "Manufactured article" is any manufactured product (e.g., package or container) or kit comprising at least one reagent, e.g., a drug for treating a disease or disorder (e.g., cancer), or a probe for specifically detecting the biomarker described herein. In some embodiments, the manufactured product or kit is promoted, distributed, or sold as a unit for carrying out the method described herein.
[0250] The terms “label” and “detectable label” refer to a moiety attached to an antibody or antigen that makes, for example, a reaction (e.g., binding) between members of a specific binding pair detectable. The labeled members of a specific binding pair are referred to as “detectable labeled.” Accordingly, the term “labeled binding protein” refers to a protein having an incorporated label that provides identification of the binding protein. In some embodiments, the label is a detectable marker capable of generating a detectable signal by attachment to a polypeptide of a biotinyl moiety that can be detected by visual or instrumental means, for example, by the incorporation of a radiolabeled amino acid or by labeled avidin (e.g., a fluorescent marker detectable by optical or colorimetric methods or streptavidin containing enzymatic activity). Examples of labels for polypeptides include, but are not limited to: radioisotopes or radionuclides (e.g., 3 H, 14 C, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, or 153Sm); chromogens, fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, luciferase, alkaline phosphatase); chemiluminescent markers; biotinyl groups; predetermined polypeptide epitopes recognized by secondary reporters (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal-binding domains, epitope tags); and magnetic agents, e.g., gadolideum chelates. Representative examples of labels commonly used in immunoassays include light-producing moiety, e.g., acridinium compounds, and fluorescence-producing moiety, e.g., fluorescein. In this regard, the moiety itself may not be detectably labeled but may become detectable upon reaction with another moiety.
[0251] Exemplary modified IL-2 containing polypeptide
[0252] Polypeptides comprising modified IL-2 are provided herein. In some embodiments, the modified IL-2 comprises at least one amino acid substitution that reduces the affinity of the modified IL-2 for an IL-2 receptor compared to wild-type IL-2. In various embodiments, the polypeptides comprising the modified IL-2 provided herein are agonists of IL-2R. In some embodiments, the modified IL-2 is modified human IL-2, and the IL-2R is human IL-2R. In some embodiments, the modified IL-2 binds to human IL-2R with an affinity at least 2, 3, 4, 5, 6, 7, 8, 9, at least 10, at least 20, at least 30, at least 50, or at least 100 times lower than the affinity of human wild-type IL-2 for IL-2R.
[0253] In various embodiments, the polypeptide containing modified IL-2 comprises at least one antigen-binding domain that binds to a T cell or natural killer (NK) cell antigen. In some embodiments, the polypeptide containing modified IL-2 provided herein comprises 1, 2, 3, 4, 5, 6, 7, or 8 antigen-binding domains, at least one or all of which bind to a T cell or natural killer cell antigen. In some embodiments, the polypeptide containing modified IL-2 provided herein comprises 1, 2, 3, or 4 antigen-binding domains, at least one or all of which bind to a T cell or natural killer cell antigen. In some embodiments, the polypeptide containing modified IL-2 does not bind to or activate IL-2R in the absence of an antigen-binding domain. In some embodiments, the polypeptide containing modified IL-2 binds to and / or activates IL-2R on a cell only when the polypeptide comprises an antigen-binding domain that binds to an antigen on the same cell as IL-2R.
[0254] In various embodiments, the modified IL-2 comprises at least one substitution at at least one amino acid position selected from P65, D84, E95, M23, and H16. In some embodiments, the modified IL-2 comprises substitutions at amino acid positions P65, H16, and D84. In some embodiments, the modified IL-2 comprises substitutions at amino acid positions P65, H16, D84, and M23. In some embodiments, the modified IL-2 comprises substitutions at amino acid positions P65, H16, D84, and E95. In some embodiments, the modified IL-2 comprises substitutions at amino acid positions P65, H16, D84, M23, and E95.
[0255] In some embodiments, the substitution at amino acid position P65 is selected from P65R, P65E, P65K, P65H, P65Y, P65Q, P65D, and P65N. In some embodiments, the substitution at amino acid position H16 is selected from H16A, H16G, H16S, H16T, H16V, and H16P. In some embodiments, the substitution at amino acid position D84 is selected from D84S, D84G, D84A, D84T, D84V, and D84P. In some embodiments, the substitution at amino acid position M23 is selected from M23A, M23G, M23S, M23T, M23V, and M23P. In some embodiments, the substitution at amino acid position E95 is selected from E95Q, E95G, E95S, E95T, E95V, E95P, E95H, and E95N.
[0256] In some embodiments, the modified IL-2 additionally comprises a substitution at amino acid position F42. In some of these embodiments, the substitution at F42 is selected from F42K, F42A, F42R, F42A, F42G, F42S, and F42T.
[0257] In some embodiments, the modified IL-2 further comprises at least one substitution at at least one amino acid position selected from Y45 and L72. In some such embodiments, the modified IL-2 comprises at least one substitution selected from Y45A and L72G.
[0258] In some embodiments, the modified IL-2 further comprises at least one substitution at at least one amino acid position selected from T3 and C125. In some such embodiments, the modified IL-2 comprises at least one substitution selected from T3A and C125A.
[0259] In some embodiments, the modified IL-2 comprises the substitutions P65R, H16A, and D84S. In some embodiments, the modified IL-2 comprises the substitutions P65R, H16A, D84S, and M23A. In some embodiments, the modified IL-2 comprises the substitutions P65R, H16A, D84S, and E95Q. In some embodiments, the modified IL-2 comprises the substitutions P65R, H16A, D84S, M23A, and E95Q. In some embodiments, the modified IL-2 comprises H16A-F42K; D84S-F42K; E15S-F42K; M23A-F42K; E95Q-F42K; P65R-H16A; P65R-D84S; P65R-E15S; P65R-M23A; It includes substitutions selected from P65R-E95Q; T3A-C125S; T3A-P65R-C125S; T3A-H16A-C125S; T3A-D84S-C125S; T3A-H16A-P65R-C125S; T3A-P65R-D84S-C125S; T3A-H16A-P65R-D84S-C125S; T3A-H16A-M23A-P65R-D84S-C125S; T3A-H16A-P65R-D84S-E95Q-C125S, and T3A-H16A-M23A-P65R-D84S-E95Q-C125S.
[0260] In any embodiment described herein, the modified IL-2 may be modified human IL-2. In various embodiments, the amino acid position of the substitution corresponds to the amino acid position in SEQ ID NO: 1.
[0261] In some embodiments, the modified IL-2 comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 84 and comprises one or more of the substitutions discussed herein. In some embodiments, the modified IL-2 comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected from SEQ ID NO: 3-9, 11-21, and 23-31 and comprises one or more of the substitutions discussed herein. In some embodiments, the modified IL-2 comprises an amino acid sequence selected from SEQ ID NO: 3-9, 11-21, and 23-31. In some embodiments, the modified IL-2 comprises an amino acid sequence selected from SEQ ID NOs: 3, 5-9, 12-21, and 23-31.
[0262] In some embodiments, the modified IL-2-containing polypeptide comprises at least one antigen-binding domain and an Fc region that bind to a T cell or natural killer cell antigen. In some embodiments, the modified IL-2-containing polypeptide provided herein comprises one, two, three, or four antigen-binding domains and an Fc region. In some embodiments, the Fc region mediates the dimerization of the modified IL-2-containing polypeptide under physiological conditions to form a dimer that is twice the number of antigen-binding sites. For example, a modified IL-2-containing polypeptide comprising three antigen-binding domains and an Fc region is trivalent as a monomer, but under physiological conditions, the Fc region can mediate dimerization, so that the modified IL-2-containing polypeptide exists as a hexavalent dimer under these conditions.
[0263] In various embodiments, the polypeptide containing modified IL-2 comprises a sequence selected from SEQ ID NOs: 3-9, 11-21, and 23-31. In various embodiments, the polypeptide containing modified IL-2 comprises a sequence selected from SEQ ID NOs: 3, 5-9, and 12-21, and 23-31. In various embodiments, the polypeptide containing modified IL-2 comprises SEQ ID NO: 21. In some embodiments, the polypeptide further comprises an antigen-binding domain. In some embodiments, the antigen-binding domain is humanized.
[0264] In some embodiments, at least one antigen-binding domain is a natural or natural cognate binding partner, anticalin (engineered lipocalin), Darpin, Fynomer, Centyrin (engineered fibronectin III domain), cystine-knot domain, Affilin, Affibody, or an engineered CH3 domain. In some embodiments, the natural cognate binding partner comprises a ligand or extracellular domain of the natural cognate binding partner of the tumor-associated antigen (TAA), or a binding fragment thereof, or a variant thereof that exhibits binding activity against TAA.
[0265] In some embodiments, a polypeptide comprising modified IL-2 and at least one antigen-binding domain enhances an anti-tumor T cell response or a natural killer cell response while evading Tregs, peripheral T cells, and endothelial cells. In some of these embodiments, at least one antigen-binding domain targets the modified IL-2 to activated T cells. In some embodiments, the modified IL-2 binds to and regulates IL-2R only when IL-2R is on the same cell as the antigen bound by at least one antigen-binding domain. In some embodiments, the modified IL-2 does not bind to or activate IL-2R when IL-2R is on a different cell from the cell expressing the antigen bound by at least one antigen-binding domain.
[0266] In various embodiments, the antigen-binding domain binds to a protein selected from PD-1, CTLA-4, LAG3, TIM3, 4-1BB, OX40, GITR, CD8a, CD8b, CD4, NKp30, NKG2A, TIGIT, TGFβR1, TGFβR2, Fas, NKG2D, NKp46, PD-L1, CD107a, ICOS, TNFR2, and CD16a. In some embodiments, the polypeptide containing modified IL-2 is nivolumab (BMS; PD-1); pembrolizumab (Merck; PD-1); AMP-514 (Amplimmune; PD-1); TSR-042 (Tesaro / AnaptysBio, ANB-011; PD-1); Includes the antigen-binding domains of STI-A1110 (Sorrento Therapeutics; PD-1), ipilimumab (BMS; CTLA-4); tremelimumab (AstraZeneca, CTLA-4); urelumab (BMS, 4-1BB); utomilumab (Pfizer, 4-1BB); atezolizumab (Roche, PD-L1), durvalumab (AstraZeneca, PD-L1); monalizumab (NKG2A, Innate Pharma and AstraZeneca); and BMS-986016 (Bristo-Meyers Squibb, LAG-3).
[0267] In some embodiments, the polypeptide comprises at least one antigen-binding domain that specifically binds to PD-1. In some embodiments, the polypeptide comprises at least one antigen-binding domain that specifically binds to LAG3. In some embodiments, the polypeptide comprises at least one antigen-binding domain that specifically binds to NKp46. In some embodiments, the polypeptide comprises at least one antigen-binding domain that specifically binds to NKG2D. In some embodiments, the polypeptide comprises at least one antigen-binding domain that specifically binds to CD8a.
[0268] In some embodiments, the antigen-binding domain may be humanized. Polypeptides comprising a humanized antigen-binding domain (e.g., a VHH-containing polypeptide) are useful as therapeutic molecules because the humanized antigen-binding domain and the humanized antibody reduce or eliminate the human immune response to non-human antibodies, which can lead to an immune response to antibody therapeutics and a reduction in the efficacy of the therapeutic. Generally, the humanized antigen-binding domain or the humanized antibody comprises one or more variable domains in which the CDR (or part thereof) is derived from a non-human antibody and the FR (or part thereof) is derived from a human antibody sequence. The humanized antigen-binding domain or the humanized antibody will optionally also comprise at least a portion of the human invariant region. In some embodiments, some FR residues within the humanized antigen-binding domain or the humanized antibody are substituted with corresponding residues from the non-human antibody (e.g., the antibody from which the CDR residue is derived) to restore or improve antibody specificity or affinity, for example.
[0269] Humanized antibodies and methods for producing the same are, for example, described in the literature [Almagro and Fransson, (2008) Front. Biosci It is reviewed in . 13: 1619-1633], for example, the literature [Riechmann et al ., (1988) Nature 332:323-329; Queen et al ., (1989) Proc . Natl Acad . Sci USA 86: 10029-10033; U.S. Patents No. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al ., (2005) Methods 36:25-34; Padlan, (1991) Mol. Immunol . 28:489-498 ("resurfacing" description); Dall'Acqua et al ., (2005) Methods 36:43-60 ("FR shuffling" explanation); and Osbourn et al ., (2005) Methods 36:61-68 and Klimka et al ., (2000) Br. J. Cancer It is additionally listed in , 83:252-260 (description of the “guided selection” approach to FR shuffling).
[0270] The human framework regions that can be used for humanization are, without restriction, framework regions selected using the "best-fit" method (e.g., Sims et al . (1993) J. Immunol . See 151:2296); framework regions derived from the common sequences of human antibodies of specific subgroups of heavy chain variable regions (e.g., Carter et al . (1992) Proc. Natl. Acad. Sci. USA , 89:4285; and Presta et al . (1993) J. Immunol , see 151:2623); human mature (somatically mutated) framework region or human germline framework region (e.g., Almagro and Fransson, (2008) Front. Biosci See . 13:1619-1633); and framework areas derived from FR library screening (e.g., Baca et al .,(1997) J. Biol . Chem . 272: 10678-10684 and Rosok et al .,(1996) J. Biol. Chem . Includes (see 271:22611-22618). Typically, the FR region of the VHH is replaced with a human FR region to create a humanized VHH. In some embodiments, certain FR residues of the human FR are replaced to improve one or more characteristics of the humanized VHH. A VHH domain having these replaced residues is still referred to herein as "humanized".
[0271] In various embodiments, the Fc region included in the modified IL-2-containing polypeptide is a human Fc region or is derived from a human Fc region.
[0272] In some embodiments, the Fc region included in the modified IL-2-containing polypeptide is derived from the human Fc region and includes a three-amino acid deletion in the lower hinge corresponding to IgG1 E233, L234, and L235, and is referred to herein as “Fc xELL”. The Fc xELL polypeptide is referred to as “effector silent” or “effector null” because it does not bind to FcγR, but in some embodiments, the xELL Fc region binds to FcRn and thus has an extended half-life and transcytosis associated with FcRn-mediated recycling.
[0273] In some embodiments, the Fc region contained in the modified IL-2-containing polypeptide is derived from the human Fc region and includes the mutants M252Y and M428V, referred herein as “Fc-YV”. In some embodiments, the Fc region contained in the modified IL-2-containing polypeptide is derived from the human Fc region and includes the mutants M252Y and M428L, referred herein as “Fc-YL”. In some embodiments, these mutants enhance binding to FcRn at the acidic pH of the endosome (near 6.5), while losing detectable binding at the neutral pH (about 7.2), thereby allowing for enhanced FcRn-mediated recycling and an extended half-life.
[0274] In some embodiments, the Fc region included in the IL-2-containing polypeptide modified herein comprises a mutation derived from a human Fc region and designed for heterodimerization, referred to herein as "knob" and "hole". In some embodiments, the "knob" Fc region comprises the mutation T366W. In some embodiments, the "hole" Fc region comprises the mutations T366S, L368A, and Y407V. In some embodiments, the Fc region used for heterodimerization comprises additional mutations such as the corresponding mutation Y349C on the second member of the heterodimer Fc pair and the mutation S354C on the first member of the heterodimer Fc pair forming an asymmetric disulfide. In some embodiments, one member of the heterodimer Fc pair comprises the modified H435R or H435K to prevent protein A binding while maintaining FcRn binding. In some embodiments, one member of the heterodimeric Fc pair comprises a variant H435R or H435K, while the second member of the heterodimeric Fc pair is not modified from H435. In various embodiments, the Hall Fc region comprises a variant H435R or H435K (referred to as "Hall-R" in some cases where the variant is H435R), while the Knob Fc region is not included. In some cases, the Hall-R mutation improves the purification of the heterodimeric region over the homodimeric Hall Fc region that may be present.
[0275] A non-limiting exemplary Fc region that can be used in a modified IL-2-containing polypeptide includes an Fc region comprising the amino acid sequence of SEQ ID NO: 47-83.
[0276] In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises an amino acid sequence selected from SEQ ID NOs: 3-9, 11-21, and 23-31 and an Fc region fused to the C-terminus of the amino acid sequence. In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises an amino acid sequence selected from SEQ ID NOs: 3, 5-9, 12-21, and 23-31 and an Fc region fused to the C-terminus of the amino acid sequence. In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises the amino acid sequence of SEQ ID NO: 21 and an Fc region fused to the C-terminus of the amino acid sequence. In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises an amino acid sequence selected from SEQ ID NOs: 3-9, 11-21, and 23-31 and an Fc region fused to the N-terminus of the amino acid sequence. In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises an amino acid sequence selected from SEQ ID NOs: 3, 5-9, 12-21, and 23-31 and an Fc region fused to the N-terminus of the amino acid sequence. In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises the amino acid sequence of SEQ ID NO: 21 and an Fc region fused to the N-terminus of the amino acid sequence. In some embodiments, a modified IL-2-containing polypeptide comprising at least one antigen-binding domain and an Fc region comprises an amino acid sequence selected from SEQ ID NOs: 34-43 and 46. In some embodiments, the polypeptide comprises an antigen-binding domain that binds to an antigen expressed on T cells or natural killer cells as described in SEQ ID NO: 43.In some embodiments, the polypeptide comprises an antigen-binding domain that binds to an antigen expressed on T cells or natural killer cells and SEQ ID NO: 46.
[0277] Exemplary activity of modified IL-2-containing polypeptide
[0278] In various embodiments, the modified IL-2-containing polypeptide provided herein is an agonist of IL-2R activity. Agonist activity may be determined, in some embodiments, using the method provided in the embodiments of the present invention, for example, using 293F cells or similar cells. In some embodiments, the modified IL-2-containing polypeptide provided herein is an agonist of IL-2R activity when targeted to T cells, but exhibits little to no agonist activity in the absence of targeting. In some embodiments, the modified IL-2-containing polypeptide provided herein is an agonist of IL-2R activity when targeted to NK cells and / or T cells, but exhibits little to no agonist activity in the absence of targeting. In some embodiments, the modified IL-2-containing polypeptide targeting T cells or NK cells comprises at least one antigen-binding domain that specifically binds to an antigen expressed on the T cells or NK cells.
[0279] In some embodiments, the modified IL-2-containing polypeptide provided herein is CD4 in vitro and / or in vivo + and / or CD8 + It increases the proliferation of T cells. In some embodiments, the polypeptide CD4 in the presence of Treg cells + and / or CD8 + Increases T cell proliferation. In some of these embodiments, CD4 + and / or CD8 + T cells are activated CD4 + and / or CD8 + It is a T cell. In some embodiments, the modified IL-2-containing polypeptide provided herein is a CD4 activated in vitro.+ and / or CD8 + Increases T cell proliferation. In some embodiments, the modified IL-2-containing polypeptide is CD4 in the absence of the polypeptide. + and / or CD8 + Activated CD4 compared to T cell proliferation + and / or CD8 + It increases T cell proliferation by at least 1.5 times, at least 2 times, at least 3 times, or at least 5 times. In some embodiments, the polypeptide increases activated CD4 compared to the proliferation observed in the absence of the polypeptide. + and / or CD8 + Increase T cell proliferation by at least 1.5 times, at least 2 times, at least 3 times, or at least 5 times and resting CD4 + and / or CD8 + It does not substantially increase the proliferation of T cells.
[0280] In some embodiments, the modified IL-2-containing polypeptide provided herein increases the proliferation of NK cells in vitro and / or in vivo. In some of these embodiments, the NK cells are activated NK cells. In some embodiments, the modified IL-2-containing polypeptide provided herein increases the proliferation of activated NK cells in vitro. In some embodiments, the modified IL-2-containing polypeptide increases the proliferation of activated NK cells by at least 1.5 times, at least 2 times, at least 3 times, or at least 5 times compared to the proliferation of NK cells in the absence of the polypeptide. In some embodiments, the polypeptide increases the proliferation of activated NK cells by at least 1.5 times, at least 2 times, at least 3 times, or at least 5 times compared to the proliferation observed in the absence of the polypeptide, and does not substantially increase the proliferation of quiescent NK cells.
[0281] Activated CD4 + and / or CD8 +Increased proliferation of T cells can be determined by any method in the art, e.g., the method provided in the embodiments of this invention. Non-limiting exemplary analyses are as follows. CD4 + and / or CD8 + T cells can be isolated from one or more healthy human donors. T cells are stained with CellTrace Violet (CTV), activated with an anti-CD3 antibody, contacted with a polypeptide containing modified IL-2, and then analyzed by FACS. Loss of CTV staining indicates proliferation. In some embodiments, CD4 + and / or CD8 + Increased T cell proliferation is CD4 isolated from different healthy human donors + and / or CD8 + It is determined as an average from an experimental set or from pooled T cells, such as by measuring T cell proliferation. In some embodiments, CD4 + and / or CD8 + The increase in T cell proliferation is determined from experiments performed using T cells from at least 5 or at least 10 different healthy donors, or as the average from a pool of T cells from at least 5 or at least 10 different healthy donors. In some embodiments, the modified IL-2-containing polypeptide provided herein is CD4 even in the presence of Treg cells. + and / or CD8 + Increases the proliferation of T cells.
[0282] In some embodiments, the modified IL-2-containing polypeptide provided herein is CD4 in vitro and / or in vivo + and / or CD8 + It increases CD71 expression on T cells. CD71 expression indicates T cell activation. In some embodiments, the modified IL-2-containing polypeptide provided herein increases CD4 in vitro. + and / or CD8 +It increases CD71 expression on T cells. In some embodiments, the modified IL-2-containing polypeptide increases CD4 expression compared to CD71 expression in the absence of the polypeptide. + and / or CD8 + It increases CD71 expression on T cells by at least 1.5-fold, at least 2-fold, at least 3-fold, or at least 5-fold. In some embodiments, the polypeptide increases activated CD4 compared to CD71 expression observed in the absence of the polypeptide. + and / or CD8 + Increase CD71 expression on T cells by at least 1.5-fold, at least 2-fold, at least 3-fold, or at least 5-fold, and resting CD4 + and / or CD8 + It does not substantially increase CD71 expression on T cells. In some embodiments, the polypeptide CD4 in the presence of Treg cells + and / or CD8 + Increases CD71 expression on T cells.
[0283] CD4 + and / or CD8 + Increased CD71 expression on T cells can be determined by any method in the art, e.g., the method provided in the embodiments of this invention. Non-limiting exemplary analyses are as follows. CD4 + and / or CD8 + T cells are isolated from one or more healthy human donors, stimulated with an anti-CD3 antibody, contacted with a polypeptide containing modified IL-2, and then analyzed by FACS for CD71 expression. In some embodiments, CD4 + and / or CD8 + Increased CD71 expression on T cells is CD4 isolated from different healthy human donors + and / or CD8 + It is determined as an average from an experimental set or from pooled T cells, such as by measuring CD71 expression on T cells. In some embodiments, CD4+ and / or CD8 + The increase in CD71 expression on T cells is determined from experiments performed using T cells from at least 5 or at least 10 different healthy donors, or as the average from a pool of T cells from at least 5 or at least 10 different healthy donors. In some embodiments, the modified IL-2-containing polypeptide provided herein contains CD4 even in the presence of Treg cells. + and / or CD8 + Increases CD71 expression on T cells.
[0284] In some embodiments, the modified IL-2-containing polypeptide provided herein is CD4 in vitro and / or in vivo + and / or CD8 + It increases pSTAT5 expression in T cells. pSTAT5 expression indicates T cell activation. In some embodiments, the modified IL-2-containing polypeptide provided herein is CD4 in vitro + and / or CD8 + It increases pSTAT5 expression in T cells. In some embodiments, the modified IL-2-containing polypeptide increases CD4 compared to pSTAT5 expression in the absence of the polypeptide. + and / or CD8 + It increases pSTAT5 expression on T cells by at least 1.5-fold, at least 2-fold, at least 3-fold, or at least 5-fold. In some embodiments, the polypeptide increases CD4 in the presence of Treg cells. + and / or CD8 + Increases pSTAT5 expression on T cells. CD4 + and / or CD8 + Increased pSTAT5 expression in T cells can be determined by any method in the art, for example, the method provided in the embodiments of this invention. In some embodiments, the modified IL-2-containing polypeptide provided herein CD4 even in the presence of Treg cells. +and / or CD8 + Increases pSTAT5 expression in T cells.
[0285] In some embodiments, the modified IL-2-containing polypeptide provided herein increases pSTAT5 expression in NK cells in vitro and / or in vivo. pSTAT5 expression indicates NK cell activation. In some embodiments, the modified IL-2-containing polypeptide provided herein increases pSTAT5 expression in NK cells in vitro. In some embodiments, the modified IL-2-containing polypeptide increases pSTAT5 expression on NK cells by at least 1.5-fold, at least 2-fold, at least 3-fold, or at least 5-fold compared to pSTAT5 expression in the absence of the polypeptide. In some embodiments, the polypeptide increases pSTAT5 expression in NK cells in the presence of Treg cells. The increase in pSTAT5 expression in NK cells can be determined by any method in the art, for example, the method provided in the embodiments of the present invention.
[0286] In some embodiments, the modified IL-2-containing polypeptide provided herein reduces or attenuates the inhibitory activity of regulatory T cells (Treg). In some embodiments, the modified IL-2-containing polypeptide is CD4 + and / or CD8 + Reduces Treg inhibitory activity on T cells by at least 10%, at least 20%, at least 30%, or at least 50%. Conventional CD4 + and / or CD8 + The decrease in Treg inhibitory activity on T cells can be determined by any method in the art, e.g., the method provided in the embodiments of this invention. Non-limiting exemplary analyses are as follows: Treg and CD4 + T cells are isolated from healthy human donor PBMCs after being differently labeled with fluorescent proliferative cell dyes. CD4 +T cells are stimulated with an anti-CD3 antibody, while Treg cells are incubated in the presence of the modified IL-2-containing polypeptide provided herein. The two T cell populations are co-cultured for 3 days, and CD4 + T cell proliferation and activation are monitored by flow cytometry. In some embodiments, the modified IL-2-containing polypeptide provided herein is, for example, CD4 in the presence of Treg cells but in the absence of the modified IL-2-containing polypeptide provided herein. + and / or CD8 + Compared to T cell activation and proliferation, CD4 in the presence of Treg cells + and / or CD8 + Increases T cell activation and proliferation.
[0287] polypeptide Expression and production
[0288] A nucleic acid molecule comprising a polynucleotide encoding a modified IL-2-containing binding polypeptide is provided. Thus, in various embodiments, a nucleic acid molecule encoding a polypeptide containing modified IL-2 is provided. In some embodiments, the nucleic acid molecule codes for modified IL-2 and at least one antigen-binding domain. In various embodiments, the nucleic acid molecule codes for modified IL-2 and an Fc region and, optionally, at least one antigen-binding domain. In some embodiments, the Fc region comprises a mutation designed for heterodimerization, such as a "knob" or "hole" mutation. In some embodiments, a nucleic acid molecule encoding a modified IL-2-containing polypeptide comprising modified IL-2, at least one antigen-binding domain, and an Fc region, wherein the Fc region is fused to the C-terminus of at least one antigen-binding domain and the modified IL-2 is fused to the C-terminus of the Fc region. In any of the aforementioned embodiments, the nucleic acid molecule may also code for a leader sequence directing the secretion of a modified IL-2-containing polypeptide, and this leader sequence is typically cleaved so as not to be present in the secreted polypeptide. The leader sequence may be a natural heavy chain (or VHH) leader sequence or another heterogeneous leader sequence.
[0289] Nucleic acid molecules can be produced using conventional recombinant DNA technology in the art. In some embodiments, the nucleic acid molecule is an expression vector suitable for expression in selected host cells.
[0290] A vector comprising a nucleic acid encoding the modified IL-2-containing polypeptide described herein is provided. Such vectors include, but are not limited to, DNA vectors, phage vectors, viral vectors, retroviral vectors, etc. In some embodiments, a vector optimized for the expression of the polypeptide in a desired cell type, e.g., 293F, CHO, or CHO-derived cells, or in NSO cells, is selected. An exemplary such vector is, for example, [Running Deer] et al ., Biotechnol. Prog It is listed in . 20:880-889(2004)].
[0291] In some embodiments, the modified IL-2-containing polypeptide may be expressed in prokaryotic cells, e.g., bacterial cells; or in eukaryotic cells, e.g., fungal cells (e.g., yeast), plant cells, insect cells, and mammalian cells. Such expression may be carried out, for example, according to procedures known in the art. Exemplary eukaryotic cells that may be used to express the polypeptide include, but are not limited to, COS cells including COS 7 cells; 293 cells including 293F cells; CHO cells including CHO-S, DG44. Lec13 CHO cells, and FUT8 CHO cells; PER.C6 ® It includes cells (Crucells); and NSO cells. In some embodiments, the modified IL-2-containing polypeptide may be expressed in yeast. For example, see U.S. Publication No. 2006 / 0270045 A1. In some embodiments, a specific eukaryotic host cell is selected based on its ability to make a desired post-translational modification of the polypeptide. For example, in some embodiments, CHO cells produce a polypeptide having a higher level of sialylation than the same polypeptide produced in 293F cells.
[0292] Introducing one or more nucleic acids (e.g., vectors) into a desired host cell may be achieved, without limitation, by any method including calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, etc. Exemplary methods without limitation are, for example, [Sambrook] in the literature et al ., Molecular Cloning, A Laboratory Manual, 3 rd It is described in [ed. Cold Spring Harbor Laboratory Press (2001)]. Nucleic acids can be transiently or stably transfected in a desired host cell according to any suitable method.
[0293] Host cells comprising any nucleic acid or vector described herein are also provided. In some embodiments, host cells expressing the modified IL-2-containing polypeptide described herein are provided. The modified IL-2-containing polypeptide expressed in the host cells may be purified by any suitable method. Such methods include, but are not limited to, the use of an affinity matrix or hydrophobic interaction chromatography. Suitable affinity ligands include agents that bind to the ROR1 ECD and Fc regions. For example, a protein A, protein G, protein A / G, or antibody affinity column may be used to bind to the Fc region and to purify the modified IL-2-containing polypeptide containing the Fc region. Hydrophobic interaction chromatography, for example, butyl or phenyl columns, may also be suitable for purifying some polypeptides such as antibodies. Ion exchange chromatography (e.g., anion exchange chromatography and / or cation exchange chromatography) may also be suitable for purifying some polypeptides such as antibodies. Mixed-mode chromatography (e.g., reverse-phase / anion exchange, reverse-phase / cation exchange, hydrophilic interaction / anion exchange, hydrophilic interaction / cation exchange, etc.) may also be suitable for purifying some polypeptides, such as antibodies. Many methods for purifying polypeptides are known in the art.
[0294] In some embodiments, the modified IL-2-containing polypeptide is produced in a cell-free system. Non-limiting exemplary cell-free systems are, for example, [Sitaraman et al ., Methods Mol. Biol. 498: 229-44(2009); Spirin, Trends Biotechnol. 22: 538-45(2004); Endo et al ., Biotechnol. Adv It is listed in . 21: 695-713(2003)].
[0295] In some embodiments, a modified IL-2-containing polypeptide prepared by the method described above is provided. In some embodiments, the modified IL-2-containing polypeptide is prepared in a host cell. In some embodiments, the modified IL-2-containing polypeptide is prepared in a cell-free system. In some embodiments, the modified IL-2-containing polypeptide is purified. In some embodiments, a cell culture medium containing the modified IL-2-containing polypeptide is provided.
[0296] In some embodiments, a composition comprising an antibody prepared by the method described above is provided. In some embodiments, the composition comprises a modified IL-2-containing polypeptide prepared in a host cell. In some embodiments, the composition comprises a modified IL-2-containing polypeptide prepared in a cell-free system. In some embodiments, the composition comprises a purified modified IL-2-containing polypeptide.
[0297] Exemplary method of treating a disease using modified IL-2-containing polypeptide
[0298] In some embodiments, a method for treating a disease in an individual is provided, comprising the step of administering a modified IL-2-containing polypeptide. This disease is CD4 + and / or CD8 +It includes any disease that benefits from increasing the proliferation and activation of T cells. In some embodiments, a method for treating cancer in an individual is provided. The method comprises the step of administering an effective amount of the modified IL-2-containing polypeptide provided herein to an individual. Such treatment methods may be for humans or animals. In some embodiments, a method for treating humans is provided. Non-limiting exemplary cancers that may be treated with the modified IL-2-containing polypeptide provided herein include basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colorectal cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer; digestive system cancer; glioblastoma; hepatocarcinoma; liver tumor; neoplasm in situ; kidney or renal cancer; laryngeal cancer; liver cancer; lung cancer; small cell lung cancer; non-small cell lung cancer; adenocarcinoma of the lung; squamous cell carcinoma of the lung; melanoma; Includes multiple myeloma; neuroblastoma; oral cancer; ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell carcinoma; gastrointestinal cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; and vulvar cancer; lymphoma; Hodgkin lymphoma; non-Hodgkin lymphoma; B-cell lymphoma; low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-rectal cell NHL; macrolesion NHL; mantle cell lymphoma; AIDS-associated lymphoma; Waldenström macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; and chronic myeloblastic leukemia.
[0299] The modified IL-2-containing polypeptide may be administered to the subject as needed. The frequency of administration may be determined by a person skilled in the art, such as an attending physician, based on consideration of the condition being treated, the age of the subject being treated, the severity of the condition being treated, and the general health condition of the subject being treated. In some embodiments, an effective amount of the modified IL-2-containing polypeptide is administered to the subject one or more times. In some embodiments, an effective amount of the modified IL-2-containing polypeptide is administered to the subject daily, twice a week, weekly, every two weeks, once a month, etc. An effective amount of the modified IL-2-containing polypeptide is administered to the subject at least once. In some embodiments, an effective amount of the modified IL-2-containing polypeptide may be administered several times, including several times over a course of at least one month, at least six months, or at least one year.
[0300] In some embodiments, a pharmaceutical composition comprising a modified IL-2-containing polypeptide is administered in an amount effective for treating (including preventing) cancer and / or increasing T cell proliferation. The therapeutically effective dose typically depends on the body weight of the subject being treated, their physical or health condition, the range of the condition to be treated, or the age of the subject being treated. Generally, the polypeptide may be administered in an amount ranging from about 0.05 mg / kg body weight to about 100 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered in a dose ranging from about 10 μg / kg body weight to about 100 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered in a dose ranging from about 50 μg / kg body weight to about 5 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered in a dose ranging from about 100 μg / kg body weight to about 10 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered at a dose ranging from about 100 μg / kg body weight to about 20 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered at a dose ranging from about 0.5 mg / kg body weight to about 20 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered at a dose ranging from about 0.5 mg / kg body weight to about 10 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered at a dose ranging from about 0.05 mg / kg body weight to about 20 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered at a dose ranging from about 0.05 mg / kg body weight to about 10 mg / kg body weight per dose. In some embodiments, the polypeptide may be administered in an amount of antibody in the range of about 5 mg / kg body weight or less, e.g., less than 4, less than 3, less than 2, or less than 1 mg / kg body weight.
[0301] In some embodiments, the modified IL-2-containing polypeptide may be administered in vivo by various routes, including, but not limited to, intravenous, intra-arterial, parenteral, intraperitoneal, or subcutaneous. Appropriate formulations and routes of administration may be selected depending on the intended application.
[0302] In some embodiments, treatment with a modified IL-2-containing polypeptide is achieved by increasing T cell proliferation and / or activation. In some embodiments, increasing T cell proliferation and / or activation inhibits cancer growth.
[0303] Pharmaceutical composition
[0304] In some embodiments, a composition comprising a modified IL-2-containing polypeptide is provided as a formulation with a wide range of pharmaceutically acceptable carriers (e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th ed. (2003); Ansel et al ., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7 th ed., Lippencott Williams and Wilkins (2004); Kibbe et al ., Handbook of Pharmaceutical Excipients, 3 rd (See ed., Pharmaceutical Press (2000)). Various pharmaceutically acceptable carriers, including vehicles, adjuvants, and diluents, are available. Furthermore, various pharmaceutically acceptable adjuvants, such as pH adjusters and buffers, isotonic adjusters, stabilizers, wetting agents, etc., are also available. Non-limiting exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
[0305] In some embodiments, the pharmaceutical composition comprises a modified IL-2-containing polypeptide at a concentration of at least 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, 125 mg / mL, 150 mg / mL, 175 mg / mL, 200 mg / mL, 225 mg / mL, or 250 mg / mL.
[0306] Combination therapy
[0307] The modified IL-2-containing polypeptide may be administered alone or in combination with other therapeutic agents, such as other anticancer agents. These may be provided before, substantially simultaneously with, or after (i.e., simultaneously or sequentially) other therapeutic agents. In some embodiments, the therapeutic method described herein may further include the step of administering radiation therapy, chemotherapy, vaccination, targeted tumor therapy, CAR-T therapy, oncolytic virus therapy, cancer immunotherapy, cytokine therapy, surgical resection, chromatin modification, resection, cryotherapy, antisense agents for tumor targets, siRNA agents for tumor targets, microRNA agents for tumor targets, or anticancer / tumor agents, or biological agents, such as antibodies, cytokines, or receptor extracellular domain-Fc fusions.
[0308] In some embodiments, the modified IL-2-containing polypeptide provided herein is provided concurrently with a second therapeutic agent, e.g., a PD-1 antibody. Examples of PD-1 antibodies include nivolumab (BMS); pembrolizumab (Merck); AMP-514 (Amplimmune); TSR-042 (Tesaro / AnaptysBio, ANB-011); STI-A1110 (Sorrento Therapeutics); and other agents for programmed death-1 (PD-1).
[0309] In some embodiments, the modified IL-2-containing polypeptide provided herein is provided concurrently with a second therapeutic agent, e.g., PD-L1 therapy. Examples of PD-L1 therapies include pidilizumab (CureTech, CT-011); durvalumab (Medimmune / AstraZeneca); atezolizumab (Genentech / Roche); avelumab (Pfizer); AMP-224 (Amplimmune); BMS-936559 (Bristol-Myers Squibb); STI-A1010 (Sorrento Therapeutics); and other agents for programmed death-1 ligand (PD-L1).
[0310] In some embodiments, the modified IL-2-containing polypeptide provided herein is provided in combination with agents targeting CAR-T (chimeric antigen receptor T cell) therapy, oncolytic virus therapy, cytokine therapy, and / or other checkpoint molecules, such as VISTA, gpNMB, B7H3, B7H4, HHLA2, CD73, CTLA4, TIGIT, etc.
[0311] diagnosis and treatment Unrestricted Exemplary method
[0312] In some embodiments, the method described herein is useful for evaluating a subject and / or a sample from the subject (e.g., a cancer patient). In some embodiments, the evaluation is one or more of a diagnosis, prognosis, and / or response to treatment.
[0313] In some embodiments, the method described herein includes the step of evaluating the presence, absence, or level of a protein. In some embodiments, the method described herein includes the step of evaluating the presence, absence, or expression level of a nucleic acid. The compositions described herein may be used for such measurements. For example, in some embodiments, the method described herein includes the step of contacting a sample of a tumor or cells cultured from a tumor with the therapeutic agent described herein.
[0314] In some embodiments, the evaluation may direct treatment (including treatment using the polypeptide described herein). In some embodiments, the evaluation may direct the use or withholding of adjuvant therapy after resection. Adjuvant therapy, also referred to as adjuvant treatment, is treatment provided in addition to primary, major, or initial treatment. As a non-limiting example, adjuvant therapy may be additional treatment generally provided after surgery where all detectable disease has been eliminated but a statistical risk of recurrence due to potential disease remains. In some embodiments, the polypeptide is used as adjuvant therapy in cancer treatment. In some embodiments, the antibody is used as the sole adjuvant therapy in cancer treatment. In some embodiments, the antibody described herein is withheld as adjuvant therapy in cancer treatment. For example, if a patient is unlikely to respond to the antibody described herein or has a minimal response, treatment may not be administered for the sake of quality of life and to avoid unnecessary toxicity from ineffective chemotherapy. In such cases, palliative care may be used.
[0315] In some embodiments, the polypeptide is administered as neoadjuvant therapy prior to resection. In some embodiments, neoadjuvant therapy refers to a therapy to shrink and / or attenuate a tumor prior to any surgery. In some embodiments, neoadjuvant therapy refers to chemotherapy administered to a cancer patient prior to surgery. In some embodiments, neoadjuvant therapy refers to the administration of a polypeptide to a cancer patient prior to surgery. Types of cancer for which neoadjuvant chemotherapy is generally considered include, for example, breast, colorectal, ovarian, cervical, bladder, and lung. In some embodiments, an antibody is used as neoadjuvant therapy in the treatment of cancer. In some embodiments, use is prior to resection.
[0316] In some embodiments, the tumor microenvironment considered in the method described herein is one or more of the following: tumor vascular structures; tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPCs); cancer-associated fibroblasts; perivascular cells; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen-presenting cells; T cells; regulatory T cells; macrophages; neutrophils; and other immune cells located in proximity to the tumor.
[0317] Kit
[0318] Also provided are manufactured articles and kits comprising any of the modified IL-2-containing polypeptides as described herein, and a suitable package. In some embodiments, the present invention comprises (i) a modified IL-2-containing polypeptide, and (ii) a kit having instructions for using the kit to administer the modified IL-2-containing polypeptide to an individual.
[0319] Suitable packages for the compositions described herein are known in the art and include, for example, vials (e.g., sealed vials), containers, ampoules, bottles, jars, flexible packages (e.g., sealed Mylar or vinyl bags), etc. These manufactured articles may be further sterilized and / or sealed. Unit dosage forms comprising the compositions described herein are also provided. These unit dosage forms may be stored in suitable packages in single or multiple unit doses and may also be further sterilized and sealed. Instructions provided in the kit of the present invention are typically written on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions included on a magnetic or optical storage disc) are also acceptable. Instructions regarding the use of the antibody generally include information regarding the dosage, administration schedule, and route of administration for the intended therapeutic or industrial use. The kit may further include instructions for selecting a suitable individual or treatment.
[0320] The container may be a unit dose, a bulk package (e.g., a multi-dose package), or a sub-unit dose. For example, a kit containing a sufficient dose of the molecule disclosed herein may also be provided to provide effective treatment to an individual for an extended period, such as about 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, or 9 months or longer. The kit may also include multiple unit doses of the molecule and instructions for use, and may be packaged in an amount sufficient for storage and use in pharmacies, e.g., hospital pharmacies and dispensing pharmacies. In some embodiments, the kit generally comprises a dry (e.g., lyophilized) composition that may be reconstituted, resuspended, or rehydrated to form a stable aqueous suspension of the polypeptide.
[0321] Examples
[0322] The embodiments discussed below are intended to illustrate the invention entirely and should not be construed as limiting the invention in any way. The embodiments are not intended to represent all or only experiments performed. While efforts have been made to ensure accuracy regarding the numbers used (e.g., amounts, temperatures, etc.), some experimental errors and deviations must be taken into account. Unless otherwise indicated, parts are by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure.
[0323] Examples 1: IL-2's P65R Mutations are essentially CD25 binding Remove
[0324] IL-2 mutants were designed to disrupt the CD25 interface through steric occlusion (P65R and P65E) and tested for binding to 293F cells transiently transfected with one or more components of the IL-2 receptor (CD25, CD122, and / or CD132). The mutants were compared to IL-2-F42K, a mutant reported to have reduced affinity for CD25. Increasing concentrations of fusion proteins containing wild-type human IL-2 (SEQ: 32), IL-2-F42K (SEQ: 33), IL-2-P65R (SEQ: 35), or IL-2-P65E (SEQ: 34), which are fused to the N-terminus of "knob" Fc and complexed with "hole" Fc (SEQ: 44), were added to transfected 293F cells and incubated at 4°C for 45 minutes.
[0325] Binding was substantially analyzed by flow cytometry as follows. Cells were washed once in 200 μL of FACS buffer (PBS, 2% FBS, 0.05% sodium azide), and the cell pellet was resuspended in 100 μL of surface marker staining solution (containing A647-conjugated anti-human Fcg secondary antibody at a 1:300 dilution in FACS buffer). Cells were incubated at 4°C for 45 minutes prior to the final wash and analyzed on a flow cytometer. Cell debris was excluded by FSC / SSC size exclusion, and dead cells were excluded based on their positive propidium iodide signal. Single cells were selected using FSC-A / FSC-H doublet and aggregate exclusion. Transiently transfected cells also expressed cytoplasmic EGFP, and FL1-positive cells were analyzed. An increase in MFI levels of the anti-human secondary antibody indicated IL-2 binding. FlowJo software was used for the analysis of cell populations. Subsequently, the raw mean fluorescence intensity ("MFI") for each marker was exported and analyzed using Excel and GraphPad Prism. The values were graphed, and titration curves were fitted to evaluate dose-response relationships using a non-linear regression 1-site -- total curve fit.
[0326] As shown in Figures 2a-c, the fusion protein containing the IL-2-P65E variant exhibited slightly reduced affinity for IL-2R compared to the fusion protein containing wild-type IL-2. The fusion protein containing IL-2 F42K exhibited lower affinity than the fusion protein containing IL-2-P65E, whereas the fusion protein containing IL-2-P65R exhibited the lowest affinity for heterotrimeric IL-2R (Figure 2a). Furthermore, the fusion protein containing IL-2-P65R did not exhibit detectable binding to CD25 / CD132 and bound only weakly to CD25 / CD122 (Fig. 2c), whereas the fusion protein containing IL-2-F42K maintained some affinity for CD25 / CD132 (Fig. 2b) and bound to CD25 / CD122 with greater affinity than the fusion protein containing IL-2-P65R (Figs. 2b and 2c). Thus, IL-2 mutated at P65R significantly reduced binding to CD25 containing the IL-2 receptor.
[0327] Examples 2: IL-2 variants that reduce affinity for CD122
[0328] As mentioned in Example 1, the P65R IL-2 mutant was designed to disrupt the CD25 interface via stereoocclusion. Additionally, the IL-2 mutant was designed to reduce affinity for the CD122 interface by eliminating specific contact residue interactions (e.g., D84S, E95Q, M23A, H16A, and E15S). Single or double mutants were fused to the N-terminus of a "knob" half of a heteromeric Fc (a disulfide-stabilized knob into hole containing the "hole" Fc SEQ No. 44) for monovalent IL-2 binding to IL-2R. Relative binding affinities were evaluated by transiently transfecting 293F cells with CD25 and CD122 (co-transfection with CD132 yielded similar results, but additional binding affinity reduced the observed difference in affinity). The conjugated IL-2-Fc fusion protein was detected with a fluorescent anti-human secondary antibody and analyzed by flow cytometry as substantially as described in Example 1.
[0329] As shown in Figures 3a-3b, all fusion proteins containing double IL-2 mutants incorporating F42K with mutations into the CD122 interface (SEQN: 36-39 and ), with the exception of IL-2-F42K-E15S (SEQN: 85), exhibited reduced binding affinity for CD25 / CD122 compared to those containing the single mutant IL-2-F42K (SEQN: 33).
[0330] Examples 3: IL-2-RAS( P65R , H16A , and D84S ) is IL-2R's Trimeric and Dimerity It has reduced affinity for CD122 in the context of form.
[0331] IL-2 double and triple mutants were constructed by combining the CD122 affinity-reducing mutation described in Example 2 with the P65R mutation. The IL-2 mutant was fused to the N-terminus of the "knob" half of a heteromeric Fc and paired with a "hole" Fc containing SEQ ID NO: 44 for monovalent IL-2 binding to the IL-2 receptor (IL-2R). The relative binding affinities of the resulting fusion proteins were evaluated on 293F cells transiently transfected with the IL-2R subunit as substantially as described in Example 1.
[0332] Compared to the fusion protein containing wild-type IL-2 (SEQN: 32), the fusion proteins containing IL-2-P65R-H16A (SEQN: 41) and IL-2-P65R-D84S (SEQN: 42) exhibited reduced affinity for both CD122 / CD132 (heteromer IL-2R) (Fig. 4a) and heterotrimeric IL-2R (Fig. 4b), whereas the affinity of the fusion protein containing the trivalent mutant, IL-2 P65R-H16A-D84S ("IL-2-RAS", SEQN: 43), was significantly weaker (Fig. 4a-4b). Maximum binding and EC 50 The shift in binding observed for all of these IL-2 mutants is that these mutants are on rate (EC 50 This suggests that the rightward shift and off-speed (reduced maximum coupling) were reduced.
[0333] Examples 4. IL-2-RAS acts on resting T cells and pre-activated T cells Reduced Affinity have
[0334] To isolate T cells, a non-T cell population was labeled with biotinylated anti-lineage marker antibodies against CD14, CD16, CD19, CD20, CD36, CD56, CD123, and TCRγ / δ (BioLegend) for 20 minutes at room temperature. Subsequently, magnetic streptavidin particles (100 x 10⁻⁶) were labeled for 20 minutes at room temperature. 6 The non-T cell population was depleted by incubation with 500 μl bead slurry + 500 μl cell suspension (incubation on a magnet for 2 x 8 minutes). The unbound cell supernatant contained isolated T cells.
[0335] Some of the isolated T cells (5.5 x 10⁶ in 3 mL) 6 ) was activated by incubating for 2 days in 6-well plates pre-coated with 1 μg / ml anti-CD3 OKT3 antibody (BD Biosciences), then washed with PBS / 2% FBS, and 2x10 in RPMI + 10% FBS. 6 Rested for 1 day at / mL. Resting or pre-activated T cells were used directly for binding assays. Binding of untargeted VHH-Fc isotype controls and fusion proteins containing IL-2-RAS or wild-type IL-2 fused to the C-terminus of untargeted VHH linked to heteromeric Fc to resting or pre-activated T cells was measured by flow cytometry as substantially as described in Example 1, except that the following secondary antibodies were used: AF647 anti-human Fc (1:1000), PI (1:2000), BV785-CD4 (1:300), APC / Fire-CD8 (1:500), and PE / Cy7-CD25 (1:100).
[0336] The untargeted IL-2-RAS fusion protein (including sequence number: 46) bound to resting (Fig. 5a) and pre-activated (Fig. 5b) T cells with reduced affinity compared to the fusion protein containing the untargeted VHH domain and wild-type IL-2 (including sequence number: 45). The isotype control, which does not contain IL-2, did not bind to resting or pre-activated T cells as shown in Figs. 5a and 5b.
[0337] Examples 5: IL-2-RAS is Treg about Reduced Affinity have
[0338] Regulatory T cells ("Treg") have high endogenous expression of CD122 and CD132 as well as CD25 and are highly responsive to wild-type IL-2. We measured the binding of fusion proteins to Treg containing wild-type IL-2 (including SEQ ID NO: 45) or IL-2-RAS triple mutants (including SEQ ID NO: 46) fused to the C-terminus of the "knob" half of the heteromeric Fc (disulfide-stabilized knob-into-hole) of untargeted VHH.
[0339] Treg and CD4+ T responder cells (Tresp) according to the manufacturer's instructions. EasySep Human CD4 + CD127 low CD25 + Treg cells were concentrated and isolated from fresh, healthy donor PBMCs using the regulatory T cell isolation kit (Stemcell). Tregs were generated from naive CD4+ T cells by 7 days of culture in ImmunoCult-XF T cell expansion medium supplemented with rhTGF-B1, all-trans retinoic acid, CD3 / CD28 T cell activator, and IL-2.
[0340] To distinguish between the two populations of cells, enriched Treg and CD4 +Responder T cells were labeled with the proliferation dyes CellTrace Violet (CTV) and CFSE, respectively, at 37°C for 10 minutes. After washing, Treg and CD4 + 1.5 x 10 T cells in RPMI supplemented with 10% FBS and 1X antibiotic / antifungal agent 6 The cells were resuspended at a volume of 50 μl to produce 75,000 Treg / well in a 96-well round-bottom plate. The Treg were incubated overnight at 37°C in the presence of 10 nM IL-2-RAS by flow cytometry as described in Example 1.
[0341] As shown in Fig. 6, in contrast to the fusion protein containing wild-type IL-2, the fusion protein containing IL-2-RAS did not exhibit observable binding to Treg enriched from PBMC (Fig. 6a), induced Treg (Fig. 6b), or CD4+ Tresponder (Fig. 6c).
[0342] Examples 6: IL-2-RAS on resting T cells Reduced activity have
[0343] T cells were isolated by magnetic bead separation substantially as described in Example 4, labeled with CellTrace Violet (CTV), and treated with fusion proteins comprising wild-type IL-2 (including SEQ ID NO: 45) or IL-2-RAS (including SEQ ID NO: 46) fused to the C-terminus of untargeted VHH linked to heteromeric Fc. Levels of CD4, CD8, CD71, and CTV were measured by flow cytometry. Proliferating T cells have reduced CTV levels.
[0344] As shown in Figures 7a and 7c, the concentration of the fusion protein containing IL-2-RAS required to induce resting CD4+ and CD8+ T cell proliferation was more than 100 times higher than the concentration of the fusion protein containing wild-type IL-2 or the fusion protein containing IL-2v-analyst required to achieve the same induction of proliferation.
[0345] As shown in Figures 7b and 7d, the concentration of the fusion protein containing IL-2-RAS, which is required to induce CD71 expression, a marker of T cell activation on CD8+ and CD4+ T cells, was at least 100 times higher than the concentration of the fusion protein containing wild-type IL-2 or IL-2v-analogous, which is required to achieve the same induction of activation.
[0346] T cell activation can be measured by increased levels of phosphorylated STAT5 in activated T cells. T cells were isolated by magnetic bead separation and treated for 15 minutes with a fusion protein containing wild-type IL-2 (including SEQ No. 45) fused to the C-terminus of untargeted VHH containing heteromeric Fc, or a fusion protein containing IL-2-RAS (including SEQ No. 46) fused to the C-terminus of untargeted VHH containing heteromeric Fc. Cells were fixed with BD Cytofix / Cytoperm™ (BD Biosciences), permeated in 90% ice-cold methanol, and levels of phosphorylated STAT5 ("pSTAT5") on CD4+ and CD8+ T cells were measured using flow cytometry with an anti-pSTAT5-PE antibody (1:70). Cells were co-stained with the following antibodies: anti-CD3-FITC (1:200), CD56-BV421 (1:100), CD4-BV785 (1:200), CD8-APC-Fire (1:300).
[0347] As shown in Figures 7e and 7f, the untargeted IL-2-RAS fusion protein achieved minimal phosphorylation of STAT5 in resting CD4+ and CD8+ T cells even at the highest concentration tested, whereas the untargeted IL-2-wild-type fusion protein induced STAT5 phosphorylation at a concentration more than 1000 times lower than the highest concentration tested.
[0348] Examples 7: IL-2 mutants are At Treg Reduced activity have
[0349] Tregs were isolated from PBMCs using the EasySep™ Human CD4+CD127lowCD25+ Regulated T Cell Isolation Kit (Stemcell). Tregs were targeted with CellTrace Violet, and 0.15 x 10⁶ per well (96-well, U-bottom) were added in 100 μl of RPMI / 10% FBS. 6 Cells were plated. Cells were titrated 1:4 starting at 100 nM in combination with 100 μl of fusion protein. Cells were incubated for 7 days. On day 7, proliferation and activation marker CD25 was measured by flow cytometry (Novocyte) as substantially as described in Example 1, except that the following antibodies were used: BV785-CD4 (1:300), APC / Fire-CD8 (1:500), PE / Cy7-CD25 (1:100), and PI (1:2000).
[0350] As shown in Figures 8a and 8b, a fusion protein containing wild-type IL-2 (including sequence number 45) fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc induced Treg proliferation and the expression of the activation marker CD25, but a fusion protein containing IL-2-RAS instead of wild-type IL-2 (including sequence number 46) did not.
[0351] Examples 8: Activated T cells expressing PD-1 PD-1- Targeted It is stimulated by IL-2-RAS.
[0352] The ability to bind to and stimulate PD-1-expressing T cells was tested using pembrolizumab (a conventional anti-PD-1 antibody) and a fusion protein containing a pembrolizumab analog and IL-2-RAS linked to the C-terminus of the heavy chain (see Fig. 1f).
[0353] Concentrated T cells from a healthy donor were activated substantially as described in Example 4. A 6-well plate was coated with 1 μg / ml OKT3 antibody overnight at 4°C. The next day, the plate was washed twice to remove unbound OKT3 antibody. The concentrated T cells were thawed using CTL medium and 5.5 x 10⁶ in full RPMI. 6 The cells were resuspended at cells / mL and seeded at 3 mL per well on coated plates. After 2 days, activated T cells were collected, washed once, and rested for 24 hours on medium free of OKT3 antibodies. Cells were labeled with the proliferation dye CellTrace™ Violet (CTV). After counting the T cells, 2 x 10⁶ 6 Cells were resuspended at a concentration of cells / mL. 100 μL of resuspended cells were seeded into each well of a 96-well round-bottom plate. Pembrolizumab or a pembrolizumab analog-IL-2-RAS fusion was added starting at a final concentration of 100 nM and titrated 1:5. On day 3, T cells were stained with the viability marker PI and the following fluorescently labeled antibodies at room temperature for 20 minutes: CD4-BV785, CD8-APC / Fire, CD25-PE / Cy7, CD71-FITC, and CD69-APC. Plates were read on a Novocyte flow cytometer as described in Example 7 for the measurement of proliferation and as in Example 1 for binding, and the data were exported to Excel for further analysis.
[0354] As shown in Fig. 9, the pembrolizumab analog-IL-2-RAS fusion protein stimulated CD8+ T cell proliferation (Fig. 9a) and CD4+ T cell proliferation (Fig. 9b), whereas pembrolizumab alone did not. While we do not wish to be bound by any specific theory, the biphasic nature of the observed proliferation may suggest that activity at low concentrations is attributed to PD-1-targeted activity, and increased activity at high concentrations is attributed to non-targeted activity. As shown in Figs. 9c and 9d, both pembrolizumab and pembrolizumab analog-IL-2-RAS bound to activated CD8+ and CD4+ T cells with similar affinities, except that additional binding to the fusion protein containing IL-2-RAS was observed at the top of the dilution range greater than 10 nM, which may have been mediated by IL-2-RAS binding to IL-2R.
[0355] Examples 9: Pre-blocking PD-1 on activated T cells is PD-1 Targeted Signal transmission by IL-2-RAS prevent
[0356] T cells were isolated and concentrated from a healthy donor by magnetic bead separation and activated by incubating on a plate encoded with an OKT3 antibody, substantially as described in Example 4. The cells were labeled with CTV. Pre-activated T cells were incubated with pembrolizumab, an anti-PD-1 antibody, or with a non-targeted antibody as a control to block the PD-1 binding site. Subsequently, the cells were incubated for 3 days with a fusion protein containing IL-2-RAS fused to a pembrolizumab analog, or a fusion protein containing IL-2-RAS fused to a non-targeted antibody as a control. The extent of IL-2 signaling was evaluated by measuring CD4+ and CD8+ T cell proliferation by flow cytometry, substantially as described in Example 7.
[0357] As shown in Figures 10a-10d, wild-type IL-2 induced potent proliferation of both CD8+ and CD4+ T cells, whereas CD4+ T cells and CD8+ T cells treated with pembrolizumab or fusion proteins containing IL-2-RAS and non-targeting antibodies exhibited low levels of proliferation unaffected by the pre-blocking of PD-1. In contrast, CD4+ T cells (Figures 10b and 10d) and CD8+ T cells (Figures 10a and 10c) treated with fusion proteins containing IL-2-RAS and pembrolizumab analogs exhibited significant PD-1-dependent proliferation (Figures 10a and 10b), which was blocked by pre-incubation with anti-PD-1 antibodies (Figures 10c and 10d). Therefore, the fusion protein containing IL-2-RAS and the anti-PD-1 antibody activated T cells only when PD-1 was expressed and accessible on the T cells.
[0358] Examples 10: PD-1- Targeted IL-2-RAS is Treg inhibition Overcome
[0359] CD4+ T responder cells and Tregs were isolated as described in Example 5. CD4+ responder cells were labeled with CTV, mixed with isolated Tregs in a 2:1 ratio, and activated with anti-CD3 beads (one bead per two T cells). The resulting mixture was treated for 7 days with a series of dilutions of a fusion protein comprising wild-type IL-2 fused to the C-terminus of untargeted VHH as shown in Fig. 1b, a fusion protein comprising IL-2-RAS fused to the C-terminus of untargeted VHH as shown in Fig. 1b, or a fusion protein comprising IL-2-RAS fused to an anti-PD-1 antibody (pembrolizumab analog-IL-2-RAS). Proliferation was measured substantially by flow cytometry as described in Example 7.
[0360] As shown in Figure 11, although Tresponder cells were inhibited by Tregs, a fusion protein (pembrolizumab analog-IL-2-RAS) containing untargeted wild-type IL-2, IL-2-RAS, and an anti-PD-1 antibody induced CD4+ T responder cell proliferation despite the presence of Tregs. Treating cells with the fusion protein containing IL-2-RAS and the untargeted antibody did not save proliferation to a similar degree. Untargeted IL-2-RAS was able to counteract the inhibitory effect of Tregs on Tresponders at much higher temperatures than the PD-1-targeted IL-2-RAS fusion protein. Thus, PD-1-targeted IL-2-RAS overcame the inhibitory effect of Tregs, and this activity depended on PD-1 binding expressed on T cells.
[0361] Examples 11: PD-1 Targeted IL-2-RAS does not transmit signals to the transformer does not
[0362] Apply 4 x 10 beads according to the manufacturer's recommended coating procedure 8 Coat each bead with 200 μg of PD-1 antigen. Briefly, wash the beads once in Buffer 1 (0.1 M sodium phosphate buffer, pH 7.4–8.0), then incubate in Buffer 1 containing PD-1 antigen at room temperature for 18 hours in a tube rotator. Subsequently, wash the beads four times with Buffer 2 (PBS, 0.1% BSA, 2 mM EDTA, pH 7.4). Incubate the beads in Buffer 3 (0.2 M Tris, 0.1% BSA, pH 8.5) at 37°C for 4 hours to inactivate the glassy tosyl groups. Afterward, wash the beads once in Buffer 2, and 400x10 6 Resuspend at a concentration of beads / mL.
[0363] The coated beads are incubated and washed with a fusion protein containing wild-type IL-2 or IL-2-RAS fused to an anti-PD-1 antibody. Subsequently, the beads are incubated with isolated resting T cells. IL-2 signaling is evaluated by measuring pSTAT5 levels via flow cytometry.
[0364] A fusion protein containing wild-type IL-2 bound to a bead potently activates CD8+ T cells and CD4+ T cells, whereas a fusion protein containing IL-2-RAS bound to a bead does not exhibit activity on CD4+ or CD8+ T cells up to the highest concentration tested. Therefore, T cell targeting of IL-2-RAS is required for IL-2 signaling, and the signaling of targeted IL-2-RAS does not occur trans-.
[0365] Examples 12: IL-2-RAS does not transmit signals to the transformer does not
[0366] Dilution series of untargeted wild-type IL-2 and untargeted IL-2-RAS, starting at 1000 nM and diluted 1:4, were coated onto assay plates, incubated overnight, and washed. T cells were added and incubated at 37°C for 30 minutes. The activation of CD8+ and CD4+ T cells was measured by detecting phosphorylated STAT5 levels substantially as described in Example 6.
[0367] As shown in Figures 12a and 12b, CD8+ and CD4+ T cells were activated by wild-type IL-2 trans-activated as measured by pSTAT5 induction, but untargeted IL-2-RAS could not activate them trans-activated. Although we do not wish to be bound by any specific theory, the reduced affinity of IL-2-RAS for CD25 and CD122 may have prevented the efficient binding and clustering of IL-2R to induce downstream signaling. Therefore, only the targeted IL-2-RAS fusion protein induces pSTAT5 signaling.
[0368] Examples 13: NKp46 Targeted IL-2-RAS is NK Specifically for cell proliferation Induces
[0369] The effects of a fusion protein containing IL-2-RAS fused to the C-terminus of a heteromeric scFv antibody targeting NKp46 as shown in Fig. 1h, a fusion protein containing wild-type IL-2 or IL-2-RAS fused to the C-terminus of a non-targeted VHH linked to a heteromeric Fc as shown in Fig. 1b, and a heteromeric scFv antibody targeting only NKp46 were determined on NK cells, CD4+ T cells, and CD8+ T cells.
[0370] Fresh PBMCs from healthy donors were labeled with CellTrace™ Violet and plated in 96-well round-bottom plates at a density of 200,000 cells / well. Dilutions of the fusion protein and the NKp46 scFv-Fc control were added to the plated cells and incubated at 37°C for 7 days. On day 7, cell proliferation was measured substantially as described in Example 7, except that the following antibodies were used: anti-CD3-BV785 (1:200), anti-CD56-APC (1:100), anti-CD4-PE (1:200), anti-CD8-APC-Fire (1:300), and PI (1:2000).
[0371] Additionally, fresh PBMCs from a healthy donor were treated with the same fusion protein or NKp46 scFv-Fc control and incubated at 37°C for 15 minutes. pSTAT5 levels in CD8+ T cells, CD4+ T cells, and NK cells (CD3-, CD56+) were measured by detecting phosphorylated STAT5 levels substantially as described in Example 6.
[0372] The binding of fusion proteins and NKp46 scFV-Fc controls to fresh PBMCs from healthy donors was measured substantially as described in Example 1, except that the following antibodies were used: anti-CD3-FITC (1:100), anti-CD56-BV421 (1:100), anti-CD4-BV785 (1:200), anti-CD8-APC-Fire (1:300), anti-human IgG-Alexa Fluor 647 (1:500), and PI (1:2000).
[0373] As shown in Figures 13a-13i, NKp46-targeted IL-2-RAS potently activated NK cell proliferation and activation without affecting CD4+ or CD8+ T cells. In contrast, untargeted wild-type IL-2 induced proliferation and activation of all tested lymphocytes (NK, CD4+, and CD8+ T cells). Binding of NKp46 scFV-Fc (without IL-2-RAS) did not induce NK proliferation or pSTAT5 induction. Therefore, NKp46-targeted IL-2-RAS induced cis-signaling of IL-2 on NK cells but did not trans-activate CD4+ or CD8+ T cells.
[0374] Examples 14: LAG3 Targeted IL-2-RAS is pre-activated LAG3 + T-cells stimulates
[0375] The effects on CD4+ T cells and CD8+ T cells of a fusion protein containing IL-2-RAS fused to the C-terminus of an anti-LAG3 heteromeric conventional antibody (MAb) as shown in Fig. 1g, an anti-LAG3 VHH fused to a heteromeric Fc as shown in Fig. 1b, a non-targeted VHH fused to a fusion protein containing IL-2-RAS as shown in Fig. 1b, a fusion protein containing wild-type IL-2 fused to the C-terminus of a non-targeted heteromeric Fc as shown in Fig. 1b, or an LAG3-targeted Mab (control), or LAG3-targeted VHH-Fc (control) were analyzed.
[0376] Concentrated T cells from healthy donors were stimulated with 1 μg / mL coated anti-CD3 (OKT3) and 10 μg / mL soluble anti-CD28 for 48 hours, followed by resting for 24 hours. Pre-activated cells were labeled with CellTrace™ Violet and seeded at 200,000 cells / well. Dilutions of the fusion protein and control protein were added, and the cells were incubated for 3 days. The proliferation and expression of the activation markers CD25 and CD71 were measured substantially as in Example 7 using these additional antibodies: anti-CD25-FITC (1:100) and anti-CD71-PE / Cy7.
[0377] Stimulated CD8+ T cells upregulated LAG3 by up to 45% of CD8+ T cells, whereas CD4+ T cells upregulated LAG3 by up to 22% of CD4+ T cells. In contrast, unstimulated T cells were nearly 0% positive for LAG3 expression on CD8+ or CD4+ T cells.
[0378] As shown in Figures 14a-14d, anti-LAG3 Mab-IL-2-RAS and anti-LAG3 VHH-IL-2-RAS increased CD8+ and CD4+ proliferation (Figures 14a and 14b) and activation as indicated by the expression levels of CD25 (Figures 14c and 14d) and CD71 (Figures 14e and 14f). Untargeted wild-type IL-2 was a strong inducer of CD8+ and CD4+ T cell proliferation and activation, and bound to stimulated T cells with higher affinity and saturation.
[0379] Examples 15: The IL-2 combination mutant is Non-targeted additional activity Reduces
[0380] The relative activity of untargeted IL-2 mutants was measured using HEK-Blue IL-2 reporter cells (InvivoGen). Reporter cells were treated with a dilution of IL-2 mutants fused to the C-terminus of untargeted VHH and incubated for 20 hours prior to Quanti-Blue analysis.
[0381] As shown in Figure 15, IL-2 mutants exhibited a wide range of activities. The experiments described above showed that IL-2-RAS (P65R, H16A, and D84S) had dramatically reduced binding to IL-2R compared to wild-type IL-2 (see Figures 4-6) and reduced activity compared to wild-type IL-2 (see Figures 7a-7e). IL-2-RAS with additional M23A mutations and IL-2-RAS with additional E95Q mutations exhibited reduced activity compared to IL-2-RAS, and the combination of IL-2-RAS with both M23A and E95Q had even more attenuated activity. In experiments using PD-1-expressing reporter cells, all of these reduced-affinity IL-2 mutants exhibited similar PD-1-targeted activity (data not shown), suggesting that high-affinity binding to cis-PD-1 may compensate for the reduced affinity of IL-2 mutants for IL-2R. Although the HEK-Blue IL-2 reporter system was useful for measuring relative activity, the EC2 values observed for IL-2 mutants in the reporter system 50 It shifted significantly to the left compared to primary lymphocytes, possibly due to the overexpression of IL-2R components in reporter cells compared to the lower IL-2R levels in primary cells.
[0382] The present disclosure may be embodied in other specific forms without departing from its spirit or essential features. Accordingly, the foregoing embodiments should be regarded as exemplary rather than limiting the present disclosure in all respects. Accordingly, the scope of the present disclosure is defined by the appended claims rather than by the foregoing description, and thus all variations within the meaning and scope of the equivalents of the claims are intended to be included herein.
[0383] Table of specific sequences
[0384]
[0385]
[0386]
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396] In sequences containing boxes or underscores, the box around an individual character represents an amino acid substitution for the corresponding wild-type or parent sequence; the box around a group of characters represents a linker sequence. The underlined character is the linker sequence.
Claims
Claim 1 A polypeptide comprising a modified IL-2, wherein the modified IL-2 comprises a P65R substitution, an H16A substitution, and a substitution at amino acid position D84, wherein the amino acid position corresponds to the amino acid position in SEQ ID NO:
1. Claim 2 In paragraph 1, the modified IL-2 is a polypeptide that is modified human IL-2. Claim 3 A polypeptide according to claim 1, wherein the substitution at amino acid position D84 is selected from D84S, D84G, D84A, D84T, D84V, and D84P. Claim 4 In claim 1, the modified IL-2 comprises a substitution at amino acid position M23, optionally said substitution being selected from M23A, M23G, M23S, M23T, M23V, and M23P. Claim 5 A polypeptide according to claim 1, wherein the modified IL-2 comprises a substitution at amino acid position E95, optionally said substitution being selected from E95Q, E95G, E95S, E95T, E95V, E95P, E95H, and E95N. Claim 6 A polypeptide according to claim 1, wherein the modified IL-2 comprises a substitution at amino acid position F42, optionally said substitution being selected from F42K, F42A, F42R, F42G, F42S, and F42T. Claim 7 A polypeptide according to claim 1, wherein the modified IL-2 comprises at least one substitution at at least one amino acid position selected from Y45 and L72, and optionally, the modified IL-2 comprises at least one substitution selected from Y45A and L72G. Claim 8 In claim 1, the modified IL-2 is a polypeptide comprising the substitutions P65R, H16A, and D84S; P65R, H16A, D84S, and M23A; P65R, H16A, D84S, and E95Q; or P65R, H16A, D84S, M23A, and E95Q. Claim 9 A polypeptide according to claim 1, wherein the modified IL-2 comprises at least one substitution at at least one amino acid position selected from T3 and C125, and optionally, the modified IL-2 comprises at least one substitution selected from T3A and C125A. Claim 10 A polypeptide according to claim 1, wherein the modified IL-2 comprises a set of substitutions selected from T3A-H16A-P65R-D84S-C125S; T3A-H16A-M23A-P65R-D84S-C125S; T3A-H16A-P65R-D84S-E95Q-C125S, and T3A-H16A-M23A-P65R-D84S-E95Q-C125S. Claim 11 In paragraph 10, the modified IL-2 is a polypeptide comprising the above set of substitutions and not comprising any additional substitutions. Claim 12 The polypeptide of claim 1, wherein the modified IL-2 comprises an amino acid sequence selected from SEQ ID NOs: 21, 28 and 31. Claim 13 A polypeptide according to any one of claims 1 to 10 and 12, wherein the polypeptide comprises an Fc region, and optionally, a modified IL-2 is fused to the N-terminus or C-terminus of the Fc region. Claim 14 A polypeptide according to claim 13, wherein the Fc region comprises a substitution at the carbat amino acid position T366 or the Fc region comprises at least one substitution at at least one carbat amino acid position selected from T366, L368, and Y407; optionally, the Fc region comprises a T366W substitution or the Fc region comprises T366S, L368A, and Y407V mutations. Claim 15 A polypeptide according to claim 13, wherein the Fc region comprises a substitution at a kavat position selected from S354 and Y349, and optionally, the Fc region comprises a substitution of S354C or Y349C. Claim 16 A polypeptide in which, in paragraph 13, the Fc region comprises a substitution at the kavat amino acid position H435, and optionally, the Fc region comprises a substitution selected from H435R and H435K. Claim 17 A polypeptide according to claim 13, wherein the Fc region comprises at least one substitution at at least one kavat amino acid position selected from M252 and M428, and optionally, the Fc region comprises M252Y and M428V substitutions. Claim 18 A polypeptide according to claim 13, wherein the Fc region comprises deletions of the carbat amino acids E233, L234, and L235; or the Fc region comprises at least one substitution at at least one amino acid position selected from L234, L235, and P329, and optionally, the Fc region comprises L234A, L235A, and P329G substitutions. Claim 19 A polypeptide according to claim 13, wherein the Fc region comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from SEQ ID NO: 47-83. Claim 20 In paragraph 13, the Fc region is part of the heavy chain constant region, and optionally, the heavy chain constant region is a polypeptide in which the IgG1, IgG2, IgG3, or IgG4 constant region. Claim 21 In paragraph 13, the modified IL-2 is fused to the C-terminus of the Fc region or the heavy chain constant region through a linker comprising 1 to 20 amino acids, optionally the linker comprising a glycine amino acid or a glycine and serine amino acid, a polypeptide. Claim 22 In claim 13, the polypeptide is a polypeptide comprising the amino acid sequence of SEQ ID NO: 87, 102, 103, or 104. Claim 23 The polypeptide of claim 1, wherein the polypeptide comprises at least one antigen-binding domain, or the polypeptide comprises two, three, or four antigen-binding domains. Claim 24 In paragraph 23, a polypeptide wherein at least one antigen-binding domain specifically binds to a T-cell antigen or a natural killer cell antigen. Claim 25 In paragraph 23, at least one antigen-binding domain is CD4 + T-cell antigen or CD8 + It specifically binds to T-cell antigens, and optionally, at least one antigen-binding domain is an activated CD4 + T-cells or activated CD8 + A polypeptide that specifically binds to antigens on T-cells. Claim 26 A polypeptide according to claim 23, wherein at least one antigen-binding domain specifically binds to PD-1, CTLA-4, LAG3, TIM3, 4-1BB, OX40, GITR, CD8a, CD8b, CD4, NKp30, NKG2A, TIGIT, TGFβR1, TGFβR2, Fas, NKG2D, NKp46, PD-L1, CD107a, ICOS, TNFR2, or CD16a. Claim 27 In paragraph 23, a polypeptide in which at least one or each antigen-binding domain is a human or humanized antigen-binding domain. Claim 28 In paragraph 23, a polypeptide wherein at least one or each antigen-binding domain comprises a VHH domain. Claim 29 A polypeptide according to claim 23, wherein at least one antigen-binding domain comprises a VH domain and a VL domain, optionally, at least one antigen-binding domain comprises the VH domain and the VL domain of an antibody selected from pembrolizumab, nivolumab, AMP-514, TSR-042, STI-A1110, ipilimumab, tremelimumab, urelumab, utomilumab, atezolizumab, and durvalumab. Claim 30 In claim 29, a polypeptide wherein at least one antigen-binding domain comprises a short-chain Fv (scFv). Claim 31 In claim 29, the polypeptide comprises a heavy chain constant region, a VH domain fused to the heavy chain constant region, a VL domain associated with the VH domain, optionally a VL domain fused to a light chain constant region, optionally a light chain constant region selected from kappa and lambda. Claim 32 A polypeptide in which, in paragraph 23, each antigen-binding domain is identical and / or each antigen-binding domain specifically binds to the same antigen. Claim 33 A polypeptide according to claim 23, wherein at least one antigen-binding domain specifically binds to PD-1, and at least one other antigen-binding domain specifically binds to a T-cell antigen or natural killer cell antigen other than PD-1. Claim 34 In paragraph 13, the polypeptide is a polypeptide that forms a homomer under physiological conditions. Claim 35 A polypeptide according to claim 1, wherein the modified IL-2 binds to human IL-2R with an affinity at least 2, 3, 4, 5, 6, 7, 8, 9, at least 10, at least 20, at least 30, at least 50, or at least 100 times lower than the affinity of human wild-type IL-2 to human IL-2R. Claim 36 A complex comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is the polypeptide of claim 35. Claim 37 In paragraph 36, the first polypeptide comprises a first Fc region and the second polypeptide comprises a second Fc region, optionally, each Fc region is an isotype selected from human IgG1, IgG2, IgG3, and IgG4, forming a complex. Claim 38 A complex according to claim 37, wherein each Fc region comprises a deletion of amino acids E233, L234, and L235 and / or; each Fc region comprises an H435R or H435K mutation and / or; each Fc region comprises mutations M252Y and M428L or mutations M252Y and M428V and / or; a first Fc region or a second Fc region comprises a T366W mutation and another Fc region comprises mutations T366S, L368A, and Y407V and / or; and a first Fc region or a second Fc region comprises a S354C mutation. Claim 39 A complex according to claim 37, wherein each Fc region independently comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to an amino acid sequence selected from SEQ ID NO: 47-83. Claim 40 In paragraph 36, the second polypeptide is a complex that does not contain modified IL2. Claim 41 A complex according to claim 36, wherein the first polypeptide comprises a first antigen-binding domain, an Fc region, and a modified IL-2, the first antigen-binding domain is fused to the N-terminus of the Fc region and the modified IL-2 is fused to the C-terminus of the Fc region, and the second polypeptide comprises a second antigen-binding domain and an Fc region. Claim 42 In claim 41, a) both the first antigen-binding domain and the second antigen-binding domain bind to PD-1; b) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to LAG3; c) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to CTLA-4; d) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to 4-1BB; e) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to OX40; f) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to GITR; g) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to CD8a; h) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to CD8b; i) the first antigen-binding domain binds to PD-1 and the second antigen-binding The domain binds to CD4; j) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to NKp30; k) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to NKG2A; l) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to TIGIT; m) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to NKG2D; n) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to TGFBR2; o) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to Fas; p) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to CD107a; q) the first antigen-binding domain binds to PD-1 and the second antigen-binding domain binds to NKp46;r) The first antigen-binding domain binds to CD8a and the second antigen-binding domain binds to TGFRβR2, or; s) The first antigen-binding domain binds to CD8a and the second antigen-binding domain binds to Fas, or; t) The first antigen-binding domain binds to NKG2D and the second antigen-binding domain binds to TGFRβR2, or; u) The first antigen-binding domain binds to NKG2D and the second antigen-binding domain binds to Fas, or; v) The first antigen-binding domain binds to NKG2A and the second antigen-binding domain binds to TGFRβR2, or; w) The first antigen-binding domain binds to NKG2A and the second antigen-binding domain binds to Fas, or; x) The first antigen-binding domain binds to NKp46 and the second antigen-binding domain binds to TGFRβR2, or; y) The first antigen-binding domain binds to NKp46 and the second antigen-binding domain binds to Fas, or; z) The first antigen-binding A complex wherein the domain binds to CTLA-4 and the second antigen-binding domain binds to LAG3; aa) the first antigen-binding domain binds to CTLA-4 and the second antigen-binding domain binds to Tim3; bb) the first antigen-binding domain binds to CTLA-4 and the second antigen-binding domain binds to OX40; cc) the first antigen-binding domain binds to CTLA-4 and the second antigen-binding domain binds to GITR; dd) the first antigen-binding domain binds to CTLA-4 and the second antigen-binding domain binds to CD107a; ee) the first antigen-binding domain binds to CTLA-4 and the second antigen-binding domain binds to NKp46; ff) the first antigen-binding domain binds to ICOS and the second antigen-binding domain binds to TNFR2. Claim 43 A pharmaceutical composition for use in a cancer treatment method comprising a polypeptide of any one of claims 1 to 12, 23 to 33 and 35 and a pharmaceutically acceptable carrier. Claim 44 Isolated nucleic acid encoding a polypeptide of any one of claims 1 to 12, 23 to 33 and 35. Claim 45 An expression vector containing the nucleic acid of claim 44. Claim 46 Isolated host cell containing the nucleic acid of paragraph 44. Claim 47 An isolated host cell expressing the polypeptide of any one of claims 1 to 12, 23 to 33 and 35. Claim 48 A method for producing a polypeptide, comprising the step of incubating the host cell of claim 46 under conditions suitable for expressing the polypeptide, and optionally, the step of isolating the polypeptide. Claim 49 A method for increasing CD4+ and / or CD8+ T cell proliferation, comprising the step of contacting T cells with a polypeptide of any one of claims 1 to 12, 23 to 33 and 35, wherein the CD4+ and / or CD8+ T cells are in vitro. Claim 50 An in vitro method for increasing NK cell proliferation, comprising the step of contacting NK cells with a polypeptide of any one of claims 1 to 12, 23 to 33, and 35. Claim 51 A pharmaceutical composition comprising a polypeptide of any one of claims 1 to 12, 23 to 33, and 35, wherein the pharmaceutical composition is to be used in a method for treating cancer comprising administering a pharmaceutically effective amount of said polypeptide to a subject having cancer. Claim 52 In paragraph 51, cancer is basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colorectal cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer; digestive system cancer; glioblastoma; hepatocarcinoma; liver tumor; neoplasm in situ; kidney or renal cancer; laryngeal cancer; liver cancer; lung cancer; small cell lung cancer; non-small cell lung cancer; adenocarcinoma of the lung; squamous cell carcinoma of the lung; melanoma; multiple myeloma; neuroblastoma; oral cancer; ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell carcinoma; gastrointestinal cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphoma; A pharmaceutical composition selected from Hodgkin lymphoma; non-Hodgkin lymphoma; B-cell lymphoma; low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate-grade / follicular NHL; intermediate-grade diffuse NHL; high-grade immunoblastic NHL; high-grade lymphoblastic NHL; high-grade small non-cutting cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-associated lymphoma; Waldenstrom macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); hairy cell leukemia; and chronic myeloblastic leukemia. Claim 53 In paragraph 51, the above method further comprises administering an additional therapeutic agent, optionally, the additional therapeutic agent is a pharmaceutical composition that is an anticancer agent. Claim 54 A pharmaceutical composition according to paragraph 53, wherein the anticancer agent is selected from chemotherapy agents, anticancer biological agents, radiotherapy agents, CAR-T therapy agents, and oncolytic viruses, and optionally, the anticancer biological agent is an antibody or a cytokine. Claim 55 In paragraph 53, the additional therapeutic agent is a pharmaceutical composition that is an anticancer biological agent inhibiting PD-1 and / or PD-L1 or inhibiting VISTA, gpNMB, B7H3, B7H4, HHLA2, CTLA4, or TIGIT. Claim 56 A pharmaceutical composition according to claim 51, wherein the method further comprises tumor resection and / or radiation therapy. Claim 57 delete Claim 58 delete Claim 59 delete Claim 60 delete Claim 61 delete Claim 62 delete Claim 63 delete Claim 64 delete Claim 65 delete Claim 66 delete Claim 67 delete Claim 68 delete Claim 69 delete Claim 70 delete Claim 71 delete Claim 72 delete Claim 73 delete Claim 74 delete Claim 75 delete Claim 76 delete Claim 77 delete Claim 78 delete Claim 79 delete Claim 80 delete Claim 81 delete Claim 82 delete Claim 83 delete Claim 84 delete Claim 85 delete Claim 86 delete Claim 87 delete Claim 88 delete Claim 89 delete Claim 90 delete Claim 91 delete Claim 92 delete Claim 93 delete Claim 94 delete Claim 95 delete Claim 96 delete Claim 97 delete Claim 98 delete Claim 99 delete Claim 100 delete Claim 101 delete Claim 102 delete Claim 103 delete Claim 104 delete Claim 105 delete Claim 106 delete Claim 107 delete Claim 108 delete Claim 109 delete Claim 110 delete Claim 111 delete Claim 112 delete Claim 113 delete Claim 114 delete Claim 115 delete Claim 116 delete Claim 117 delete Claim 118 delete Claim 119 delete Claim 120 delete Claim 121 delete Claim 122 delete Claim 123 delete Claim 124 delete Claim 125 delete
Citation Information
Patent Citations
Improved interleukin-2 muteins
WO2005086798A2
